Development and validation of a high-throughput system for the genotyping of Hepatitis C Virus by Zancan, Irene
  
 
University of Padova 
Department of Pharmaceutical and  
Pharmacological Sciences 
 
DOCTORAL COURSE IN PHARMACOLOGICAL SCIENCES 
CURRICULUM PHARMACOLOGY, TOXICOLOGY AND THERAPY 
XXIX CYCLE 
 
Development and validation of a                              
high-throughput system for the genotyping of 
Hepatitis C Virus 
 
Thesis realized with the financial support of Centro Ricerche Scientifiche Dott. Dino 
Paladin 
 
 
COORDINATOR: Prof. Piero Maestrelli 
SUPERVISOR: Prof. Pietro Giusti 
EXTERNAL SUPERVISOR: Dr. Dino Paladin 
 
 
Ph.D. STUDENT: Irene Zancan 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE OF CONTENTS 
 
ABSTRACT ................................................................................................................. 6 
ABBREVIATIONS AND ACRONYMS ............................................................................. 7 
1. INTRODUCTION: THE IMPORTANCE OF HCV GENOTYPING ................................... 9 
1.1.PAVING THE WAY FOR PERSONALIZED MEDICINE ........................................... 9 
1.2. INTRODUCING THE HEPATITIS C VIRUS ......................................................... 11 
1.2.1. HISTORY AND TAXONOMY ...................................................................... 11 
1.2.2 GENOME AND VIRAL STRUCTURE ............................................................ 13 
1.2.3. LIFE CYCLE ................................................................................... …………. 16 
1.2.4. CLINICAL INFECTIONS ................................................................. …………. 18 
1.3. THE IMPORTANCE OF HCV GENETIC VARIABILITY ......................................... 23 
1.3.1 CLASSIFICATION: GENOTYPE, SUBTYPE AND QUASISPECIES .................. 23 
1.3.2 CLINICAL IMPLICATIONS ........................................................................... 24 
1.4. TREATMENT OF HCV INFECTION .................................................................. 26 
1.4.1 INTRODUCTION: THE IFNα ERA AND THE NEW GENERATIONS OF DIRECT 
ACTING ANTIVIRAL DRUGS ................................................................................ 26 
1.4.2 DIRECT ANTIVIRAL AGENTS: AN IMPORTANT BREAKTHROUGH ............ 28 
1.4.2.1 CLASSIFICATION AND MECHANISMS OF ACTION……………................28 
1.4.2.2 CONTRAINDICATIONS: DRUG-DRUG INTERACTION ….…………..……..30 
1.4.2.3 CLINICAL DATA…………………………………………………….. ….…………..……..31 
1.4.2.4 STATE OF ART ……………….…………………………………………………….……….36 
1.5. DIAGNOSIS OF HCV INFECTION .................................................................... 38 
1.5.1 INDIRECT ASSAYS ...................................................................................... 38 
1.5.2 DIRECT ASSAYS .......................................................................................... 41 
1.5.3 GENOTYPING AND SUBTYPING ASSAYS ................................................... 44 
1.5.4 RAVs DETECTION ...................................................................................... 45 
2. AIM OF THE STUDY ............................................................................................. 46 
3. PART I: AUTOMATED EXTRACTION KIT DEVELOPMENT ................................... 47 
3.1 MATERIALS AND METHODS ........................................................................... 50 
3.1.1 GENEQUALITY X120 .................................................................................. 47 
4 
 
3.1.2 EXTRACTION PROTOCOL DESIGN ............................................................. 48 
3.1.3 PACKAGING DESIGN .................................................................................. 49 
3.1.4 NUCLEIC ACIDS EXTRACTION WITH BIOROBOT EZ1 ................................ 49 
3.1.5 NUCLEIC ACIDS EXTRACTION WITH NUCLISENSE .................................... 49 
3.1.6 SAMPLES .................................................................................................... 50 
3.1.7 REAL TIME PCR KIT FOR PATHOGEN QUANTITATIVE DETECTION .......... 51 
3.2 RESULTS ........................................................................................................ 53 
3.2.1 OPTIMIZATION OF EXTRACTION PROTOCOL............................................ 53 
3.2.1.1 EVALUATION  OF EXTRACTS QUALITY…………………………………………..54 
3.2.1.2 EVALUATION OF OPTIMAL STARTING VOLUMES………………………… 54 
3.2.1.3 EVALUATION OF OPTIMAL ELUTION VOLUMES……………………………55 
3.2.1.4 EVALUATION OF OPTIMAL CARRIER CONCENTRATION………………..56 
3.2.1.5 EVALUATION OF THE ABSENCE OF CROSS-CONTAMINATION………57 
3.2.2 VALIDATION OF GENEQUALITY X120 PATHOGEN KIT PROTOTYPE......... 59 
3.2.2.1 REPEATIBILITY AND REPRODUCIBILITY EVALUATION……………………59 
3.2.2.2 ANALYTICAL SENSITIVITY EVALUATION………………………………………..60 
3.2.2.3 LINEARITY RANGE EVALUATION…………………………………………………..62 
3.2.2.4 EXTRACTION EFFICIENCY EVALUATION………………………………………..63 
4. PART II: EVALUATION OF HCV GENOTYPING WITH AMPLIQUALITY HCV TYPE PLUS 
DEVICE………………………………………………………………………………………………………..………  65 
4.1 MATERIALS AND METHODS .......................................................................... 65 
4.1.1 AMPLIQUALITY HCV TYPE PLUS KIT .......................................................... 65 
4.1.2 AUTOBLOT ................................................................................................. 67 
4.1.3 GENEQUALITY X120 PATHOGEN KIT ......................................................... 68 
4.1.4 SEQUENCING NS5B REGION ..................................................................... 68 
4.1.5 ANALYSIS OF HCV RNA EXTRACTS WITH THE ARTUS HCV RG RT-PCR Kit…
 .......................................... ……………………………………………………………………………69 
4.1.6 SAMPLES .................................................................................................... 69 
4.1.7 INTERFERING SUBSTANCES ....................................................................... 70 
4.2 RESULTS ........................................................................................................ 71 
4.2.1 REPEATIBILITY AND REPRODUCIBILITY EVALUATION .............................. 71 
4.2.2 ANALYTICAL SPECIFICITY EVALUATION .................................................... 72 
5 
 
4.2.3 ANALYTICAL SENSITIVITY EVALUATION ................................................... 74 
4.2.4 DIAGNOSTIC SPECIFICITY EVALUATION ................................................... 75 
4.2.5 DIAGNOSTIC SENSITIVITY EVALUATION................................................... 75 
4.2.6 INTERFERING SUBSTANCES EVALUATION ............................................... 78 
5. DISCUSSION ..................................................................................................... 80 
REFERENCES ........................................................................................................ 84 
APPENDICES ........................................................................................................ 94 
AKNOWLEDGEMENTS ....................................................................................... 101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
ABSTRACT 
 
The subject of this dissertation is the work I carried out at the Università degli Studi di 
Padova in collaboration with the CRS (Centro Ricerche Scientifiche) Dott. Dino Paladin, 
where I conducted part of the project. The CRS Dott. Dino Paladin is a center specialized 
in biotechnology research and that collaborates with AB ANALITICA srl for the 
commercialization of the developed diagnostic CE IVD devices.  
My PhD project is focused on the development of a standardized and performing 
procedure for the Hepatitis C Virus (HCV) genotyping. HCV is a small, enveloped, 
positive sense single-strand RNA virus belonging to Flaviviridae family and it is the 
etiologic agent of the so called post-transfusion non-A, non-B hepatitis. The World 
Health Organization (WHO) evaluates more than 130-150 million of persons worldwide 
that are chronically HCV infected, and the morbidity and mortality attributable to HCV 
infection continues to increase. Although the research aims to formulate a 
pangenotypic anti-viral regimen, nowadays the HCV genotype information is still 
required to choose the best anti-viral treatment for the patient. Because of the high 
demand for this type of analysis, we decided to design and develop a high-throughput 
process for the HCV genotyping, starting from the clinical sample up to the genotype 
result. 
In the first part of my PhD work, I dealt with the development of an automated process 
for the extraction of pathogen nucleic acids. In particular, we developed the 
GENEQUALITY X120 Pathogen kit to use with the automated platform GENEQUALITY 
X120 (AB ANALITICA srl). This kit revealed extraction efficiency for both pathogen DNA 
and RNA and therefore it has been chosen for the HCV RNA extractions. 
In the second part of my study, I focused on the performance evaluation of the 
AMPLIQUALITY HCV TYPE PLUS device, which is a kit based on a Reverse Line Blot (RLB) 
technique intended for the genotyping of HCV. The results revealed genotyping and 
subtyping efficiency. The developed kits are currently CE IVD marked and 
commercialized. 
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1. INTRODUCTION: THE IMPORTANCE OF HCV GENOTYPING 
 
1.1. PAVING THE WAY FOR PERSONALIZED MEDICINE 
 
DEFINING PERSONALIZED MEDICINE 
 
 
‘It’s far more important to know what person the disease has than what disease the 
person has.’ Hippocrates [1] 
The concept of personalized medicine dates back many hundreds of years. It was not 
until the 19th century, however, that developments in chemistry, histochemistry and 
microscopy allowed scientists to begin to understand the underlying causes of diseases. 
In this period, Sir William Osler (1849-1919) recognized that: 
‘variability is the law of life, and as no two faces are the same, no two bodies are alike, 
and no two individuals react alike, and behave alike under the abnormal conditions we 
know as disease’ [2]. 
Moreover, a few decades later, it was introduced for the first time the concept of 
‘factors of risk’ with The Framingham Study, where it was studied a population 
composed of individuals with a higher risk then other of developing a specific disease 
[3]. 
To date, several advances in the scientific knowledge led an important breakthrough: as 
a result of the Human Genome Project [4,5] and of the HapMap Project [6,7], it was 
sequenced and mapped the entire human genome. In addition, great strides have been 
made in mapping the molecular pathways. All these findings have driven the rise of a 
new predictive science, called personalized medicine. 
Personalized medicine is a broad and rapidly advancing field of health care for which 
each person has unique clinical, genetic, genomic and environmental information. The 
main goal of personalized medicine is to optimize medical care and outcomes for each 
individual, including prevention strategies, medication types, treatments and dosages, 
which differ from person to person. 
The interindividual variability regards the drug response too. All patients do not respond 
to the same medicine in the same way. In the past, the differences in the risk-benefit 
ratio between patients taking the same drug was attributed to non genetic factors such 
as age, sex, nutritional states, general medical condition and lifestyle. Today, in addition 
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to these factors, the differences in patient genetic make-up have been recognized to 
play an important role in the individual response to drug. 
In conclusion, we are witnessing a transition from a ‘trial-and-error medicine’, for which 
doctors prescribed drugs empirically changing the dosage or trying another one if the 
original was inefficient, to a new era of individualized medicine, for which doctors have 
the tools to predict the factor risk of the patient for a disease and eventually its 
response to therapies. 
 
HCV AND PERSONILEZED MEDICINE  
 
Regarding the infectious diseases, an important aspect to consider before treating the 
patient is the physiology of the etiologic agent. The great ability of microorganisms to 
evolve constantly to survive to the external environment is due to their high genetic 
variability, which exists at several different levels. In fact, a unique virus species 
branches out in genotypes, which are divided also in a wide range of subtypes. The 
substantial genetic divergence that distinguishes these viral subgroups entails 
differences in their protein set, for example in their membrane glycoproteins or non-
structural proteins. To date, these viral proteins are the major targets of the antiviral 
drugs.  
Although the antiviral drugs have become increasingly more selective over time, they 
may be more, less or not effective depending on the genotype of the virus. This 
phenomenon is called antiviral drug resistance and, as abovementioned, it depends on 
the protein set hence on the genetic make-up of the specific viral subgroup.  
Hepatitis C virus (HCV), the subject of my dissertation, is a representative example of 
what is described in this paragraph. In 2015, AIFA (Agenzia Italiana del Farmaco) in 
collaboration with AISF (Associazione Italiana per lo Studio del Fegato) introduced a new 
algorithm for the therapy of chronic hepatitis C [8]. The AIFA-AISF algorithm shows the 
optimal therapeutic options for the use of several anti-HCV drugs, considering also the 
genotype of HCV. 
In summary, personalized medicine considers not only the conditions of the individual 
patient, but also, in case of infective diseases, the genetic make-up of the etiologic 
agent. Indeed, an understanding as comprehensive as possible about patient’s 
information, general medical conditions, genetic markers and disease is necessary to 
optimize his therapy, prescribing him the right drug at the right dose at the right time. 
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1.2. INTRODUCING THE HEPATITIS C VIRUS 
 
1.2.1. HISTORY AND TAXONOMY 
 
Evidence of the existence of Hepatitis C virus (HCV) dates back about to 40 years old, 
when it was known that neither Hepatitis A virus (HAV), nor Hepatitis B virus (HBV) were 
the etiologic agent of the 65% of post-transfusion hepatitis. Several studies [9,10] 
identified HCV as the responsible of these post-transfusion non-A, non-B hepatitis and 
its genome was cloned for the first time in 1989 [11]. 
HCV is a small, enveloped, positive sense single-strand RNA virus, member of 
Hepacivirus genus, belonging to Flaviviridae family. The comparative analysis among 
HCV nucleotide sequences, recovered from infected individuals from different 
geographical regions, revealed the presence of at least seven major genetic groups (1-
7), in other words genotypes, and a several number of subtypes (67 confirmed and 20 
provisional) [12]. (Fig 1).  
Regarding HCV global geographic distribution (Fig. 2), the genotype 1 is estimated to 
account 83.4 million (46.2%) of infected cases, with over one-third located in East Asia. 
The genotype 3 is the next most common and there are about 54.3 million (30.1%) 
cases globally, approximately three-quarters of which occur in south Asia; the remaining 
are located in parts of Scandinavia. Genotypes 2, 4, and 6 are responsible for the 
majority of the remaining cases of HCV worldwide, with an estimated 16.5 million 
(9.1%), 15.0 million (8.3%), and 9.8 million (5.4%) cases, respectively. East Asia accounts 
for the greatest numbers of genotype 2 and genotype 6 HCV cases, while North Africa 
and the Middle East have the largest number of genotype 4 cases. Genotype 5 is 
responsible for the fewest HCV cases globally (1.4 million, <1% of all HCV cases), the 
great majority of which occurs in Southern and Eastern sub-Saharan Africa. Finally, 
genotype 6 is present at the highest frequencies in East and Southeast Asia, but is the 
dominant genotype in only one country, Laos; it is also prevalent in neighboring 
Vietnam [12].To date, only one genotype 7 infection has been reported; it was isolated 
in Canada from a Central African immigrant [15]. 
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Fig 1. Phylogenetic tree of 129 representative complete coding region sequences. Up to two representatives of each 
confirmed genotype/subtype were aligned and a neighbor joining tree constructed using maximum composite 
likelihood nucleotide distances between coding regions using MEGA5.Sequences were chosen to illustrate the 
maximum diversity within a subtype. Tips are labeled by accession number and subtype (*unassigned subtype). For 
genotypes 1, 2, 3, 4, and 6, the lowest common branch shared by all subtypes and supported by 100% of bootstrap 
replicates (n= 1,000) is indicated by● [14] 
 
 
Fig 2. Valuation of the prevalence of HCV infection worldwide and global geographic distribution of HCV genotypes. 
Data could be underestimated inasmuch HCV infection may remain asymptomatic also for many years [16]. 
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1.2.2 GENOME AND VIRAL STRUCTURE 
 
HCV consists in a virion of 50-55nm of diameter, composed of a double-layer lipid 
envelope to which the glycoprotein E1 and E2 are anchored. This envelope surrounds a 
nucleocapsid of 30-35 diameter made up of multiple copies of a core protein, within 
which the viral genome is conserved [17] (Fig. 3). 
 
 
Fig. 3. Structure of a HCV virion. 
 
HCV is a positive single-stranded RNA virus, which genome consists in approximately 
9400 nucleotides in length. The genome contains a single ORF (Open Reading Frame), 
which is translated into a polyprotein of 3000 aminoacids. This polyprotein is 
subsequently processed by viral and host proteases into three structural proteins (core, 
E1 and E2), seven non-structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5 and NS5B) 
and an additional protein ARF (Alternate Reading Frame) derived from a -2/+1 
ribosomal frameshift, which probably occurs at, or near to, codon 11 of the core protein 
sequence [18]. The genes encoding the structural proteins are located at 5’ of the ORF 
and the genes encoding the non-structural proteins follow them downstream. 
The ORF is flanked by the 5’- and 3’-untranslated regions (5’-UTR/NCR and 3’-UTR/NCR), 
which regulates the viral replication. The 5′-UTR is highly conserved among different 
HCV isolates and it is composed by four highly ordered domains numbered from I to IV. 
Domains II, III and IV constitute the IRES that is essential for cap-independent 
translation of the viral RNA. Domain I is essential for HCV RNA replication, too [19]. The 
3′-UTR consists in three functional regions: a short variable region (about 40 
nucleotides), a poly (U/UC) tract with an average length from 30 to 80 nucleotides, and 
an almost invariant 98 nucleotides RNA element, designated the X-tail. The conserved 
elements in the 3′-UTR, including a minimal poly (U) tract of about 25 bases, are 
essential for the viral replication [20]. Besides the 5′- and 3′-UTRs, an essential cis-acting 
replication element (CRE) was identified in the sequence that encodes the C-terminal 
region of NS5B [21]. 
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The genetic organization and the polyprotein processing of hepatitis C virus (HCV) are 
shown in the figure 4 (Fig. 4). 
 
 
Fig. 4. The 9.6-kb positive-strand RNA genome is schematically depicted at the top. Simplified RNA secondary 
structures in the 5′- and 3′-UTR and the core gene are shown. Internal ribosome entry site (IRES)-mediated 
translation yields a polyprotein precursor that is processed into the mature structural and non-structural proteins. 
Amino-acid numbers are shown above each protein (HCV H strain; genotype 1a; GenBank accession number 
AF009606). Solid diamonds denote cleavage sites of the HCV polyprotein precursor by the endoplasmic reticulum 
signal peptidase. The open diamond indicates further C-terminal processing of the core protein by signal peptide 
peptidase. Arrows indicate cleavages by the HCV NS2–3 and NS3–4A proteases. Dots in E1 and E2 indicate the 
glycosylation of the envelope proteins [20]. 
 
FUNCTION OF STRUCTURAL PROTEINS 
 
The CORE protein forms the viral nucleocapside and, moreover, it takes part into the 
cell-signaling regulation as well as into viral assembly and RNA transduction [22,23]. An 
internal signal sequence located between the CORE and E1 sequences targets the 
nascent polypeptide to the endoplasmic reticulum (ER) membrane for translocation of 
the E1 ectodomain into the ER lumen, where the cleavage of the signal sequence by 
signal peptidase yields an immature 191 aminoacids CORE. Further C-terminal 
processing yields the mature 21-kDa protein of 173–179 aminoacids. The N-terminal 
hydrophilic domain (D1) of the mature CORE contains a high proportion of basic 
aminoacid residues and has been implicated both in RNA binding and homo-
oligomerization. The CORE is a α-helical protein that is found on membranes of the ER 
and on the surface of lipid droplets. The association with lipid droplets, which is 
mediated by the central, relatively hydrophobic domain (D2), may have a role during 
viral replication and/or virion morphogenesis [24]. 
The envelope proteins E1 and E2 are glycosylated and form a non-covalent complex, 
which is the building block for the viral envelope. HCV glycoprotein maturation and 
folding is a complex process that involves the ER chaperone machinery and depends on 
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disulphide bond formation as well as glycosylation process. The transmembrane 
domains of E1 and E2, located at their C-terminal, are involved in heterodimerization 
and they have ER retention properties. Each of them contains a hydrophobic patch that 
functions as an internal signal peptide for the downstream E2 and p7 proteins [25]. 
Comparative analysis among E1 and E2 nucleotide sequences show a high 
hypervariability in particular in two regions of E2 (HVR1 and HVR2). These HVRs play an 
important role in the viral life cycle and in the viral evasion from the immune system. 
 
FUNCTION OF NON-STRUCTURAL PROTEINS 
 
The p7protein is a 63 aminoacids polypeptide that is often incompletely cleaved from 
the E2. The p7 is not required for RNA replication in vitro but is essential for productive 
infection in vivo. It has been suggested that belongs to the viroporin family and that 
could have an important role in viral particle maturation and release [26]. 
The NS2 protein is an auto-protease (cysteine-protease) which intervenes in the initial 
phases of the viral assembly and morphogenesis, probably interacting with 
glycoproteins E1 and E2, and with NS3/NS4A. Moreover, it interacts with other cell 
proteins, as CIDE-B, to inhibit apoptosis of the host cell [27]. 
The NS3 protein is a multifunctional enzyme, with an N-terminal protease activity, 
including a catalytic serine, and a C-terminal helicase and NTPase activities. These 
protease and helicase domains are independent structural units connected by a linker 
region. The NS3 acts in complex with the NS4A polypeptide, which is a non-covalently 
bound cofactor, that enhance the protease activity. NS3/4A takes part into the 
processing of the viral polyprotein [28]. 
The NS4B protein is a relatively poorly characterized 27-kDa protein, whose function is 
to induce the formation of the membranous network, a specific membrane alteration 
that serves as a scaffold for the HCV replication complex [29]. 
The NS5A protein is a multifunctional phosphoprotein that can be found in basally 
phosphorylated (56 kDa) and hyperphosphorylated (58 kDa) forms. It has an important 
role in the HCV life cycle and probably modulates the efficiency of HCV RNA replication; 
in fact, the NS5A would attach the viral RNA onto intracellular membranes and 
coordinate its different fates during HCV replication [30]. 
The NS5B protein is the viral RNA-dependent RNA polymerase (RdRp) and it is the key 
enzyme responsible for HCV replication. The NS5B utilizes the HCV RNA genome as a 
template for RNA synthesis without a need of a primer. Initiation of RNA synthesis is 
slow and accompanied by frequent dissociation events. Formation of the first 
phosphodiester bond stabilizes the complex, which then passes to the elongation 
phase. These functionally distinct complexes are associated to distinct conformations 
and subdomains of the enzyme, such as ‘thumb’, ‘fingers’ and ‘palm’, which are the 
major target for the antiviral intervention. Moreover, this enzyme lacks of a 
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proofreading function; this feature, together with the high replicative activity, accounts 
for genetic variability of HCV [31]. 
 
1.2.3 LIFE CYCLE  
 
Hepatocytes are the main target cells of HCV, but infection of B cells, dendritic cells and 
other cell types has also been reported. Different types of receptors and molecules 
mediate the entry of the virus into hepatocytes, such as CD81, a tetraspanin protein 
found on the surface of many cell types, the LDL receptor (LDLR), the scavenger 
receptor class B type I (SR-BI), claudin-1 (CLDN1), occludin (OCLN)and others, but their 
role remains still not fully elucidated [32,33,34]. 
Virus internalization depends on clathrin-mediated endocytosis and the acid pH of the 
endosome induces the fusion between the viral envelope and the endosomal 
membrane, culminating in the release of the viral RNA into the cytoplasm of the host 
cell. At this point, the translation of the viral proteins starts. 
The positive single-stranded RNA of HCV is translated directly without additional 
passages. The viral IRES consists in domains II, III and IV of the 5′-UTR, together with the 
first 24–40 nucleotides of the CORE-coding region. The 40S ribosomal subunit 
recognizes and attaches the viral IRES to form a 48S complex in association with the 
eukaryotic translation initiation factor3 (eIF3) and the ternary complex (eIF2•Met-
tRNAi•GTP) [20]. This pre-initial complex summons the 60S ribosomal subunit to 
activate the translation process.  
Translation of the HCV ORF yields a polyprotein precursor that is co- and post-
translationally processed by cellular and viral proteases into the mature structural and 
non-structural proteins. The structural proteins and the p7 polypeptide are processed 
by the ER signal peptidase whereas the non-structural proteins are processed by two 
viral proteases, the NS2 and the NS3 [20]. 
After the translation process, the viral RNA replication happens. Starting from the viral 
single-stranded RNA, NS5B provides to the development of a double stranded filament, 
which is successively separated by NS3, achieving the RNA antisense, which functions as 
template for the synthesis of the new RNA molecules. When all viral components are 
ready, they are assembled at the ER to arrange complete viral particles.  
Although their role is not well understood, the membranes and the lipid droplets (LD) 
play a key role in the viral life cycle. Several functions have been suggested: physical 
support and organization of the RNA replication complex, compartmentalization and 
local concentration of viral products, attachment of the viral RNA during unwinding, 
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provision of lipid constituents important for replication and protection of the viral RNA 
from double-strand RNA-mediated host defenses or RNA interference [20]. 
 
 
Fig. 5. The HCV life cycle can be summarized in the following steps:  1. Entry into the host cell; 2. Uncoating of the 
viral RNA; 3. Translation and polyprotein processing; 4. Viral RNA replication; 5. Viral particles assembly; 6. Release of 
the new virions. 
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 1.2.4 CLNICAL INFECTIONS 
 
EPIDEMIOLOGY  
 
Globally, the morbidity and mortality attributable to HCV infection continues to 
increase. According  to  estimates  from  the  Global  Burden  of  Disease  study,  the  
number  of  deaths  due  to hepatitis  C  was  333.000  in  1990,  499.000  in  2010  and  
704.000  in  2013 [35,36]. The increase in number of deaths reflects the high incidence 
of hepatitis C during the mid-twentieth century, which is thought to have increased 
dramatically starting in the 1940s due to the expanded use of parenteral procedure and 
injection drug use [37]. The incidence declined in the 1990s following the discovery of 
the HCV, resulting in the introduction of screening of blood HCV, improvements in 
infection control and safer injection practices. Despite the declining incidence, a large 
number of persons who were infected 30-60 years ago are now dying from HCV-related 
complications. 
More recent analyses of the global prevalence of HCV indicate that there may be fewer 
persons living with HCV infection than previously estimated. In 2013, a systematic 
review concluded that there were 184 million persons with a history of HCV infection 
(presence of anti-HCV antibody) [38]. Of those, an estimated 130-150 million may be 
chronically infected (HCV-RNA positive). A more recent systematic review that excludes 
older studies estimates 115 million persons are anti-HCV antibody positive and 80 
million have chronic infection (Appendix 1) [39]. This lower estimate may be explained 
by a declining incidence as well as improved diagnostic serological test for HCV, 
resulting in fewer false-positive results.  
If correct, this lower burden of disease would be lower than previously thought; 
nevertheless, the number of people needing treatment remains high. There are also 
improved estimations of the prevalence of HCV in Africa [40]. 
 
NATURAL HISTORY  
 
HCV is primarily transmitted through percutaneous exposure to blood. Its infection is 
strongly associated with health inequity: in fact, it is most commonly caused by unsafe 
injection practices and procedures such as renal dialysis and unscreened blood 
transfusions. Data show that over 16 billion injections are administered yearly 
worldwide and 40% of these are considered to be unsafe (mainly in sub-Saharan Africa 
and Asia)[43]. Secondly, in middle- and high-income countries, most HCV infections 
occur among people who use unsterile equipment to inject drugs and contaminated 
drug solutions, in effect of the estimated 16 million people in 148 countries who 
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actively inject drugs, 10 million have serological evidence of an HCV infection [44]. 
Other modes of transmission of HCV include cosmetic procedure (such as tattooing and 
body piercing), scarification, circumcision and sexual transmission, which is more 
common in HIV-positive persons, particularly in men who have unprotected sex with 
men [45]. Finally, the risk of transmission of HCV from an infected mother to her child is 
about 4-8%[46].  
HCV causes both acute and chronic hepatitis. The incubation of HCV before developing 
the acute infection is about 6-12 weeks. The acute infection is usually asymptomatic, 
and it is rarely associated with life-threatening diseases. About 25-45% of infected 
persons spontaneously clear the virus within six months of the infection without any 
treatment. Almost all the remaining 55-86% of persons will develop chronic HCV 
infection. Left untreated, chronic HCV infection can cause liver cirrhosis, liver failure and 
HCC (HepatoCellular Carcinoma) (Fig. 6). Of those with chronic HCV infection, the risk of 
developing cirrhosis is about 20%, instead the risk of HCC in persons with cirrhosis is 
approximately 2-4% per year [47]. These risks, however, can vary, depending upon 
certain patient characteristics or behaviours, as excess in alcohol consumption, HBV/HIV 
co-infections or immunosuppression [48], conditions that accelerate progression of liver 
disease in infected persons. 
 
 
Fig. 6. Natural history of HCV infection [47]. 
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The persistent inflammation of the liver due to chronic HCV infection involves a 
progressing disease in which the liver tissue is replaced with a fibrotic one. The stage of 
liver fibrosis can be estimated with the liver biopsy-scoring system METAVIR: a score 0-2 
indicates a mild fibrosis without a compromised functionality, whereas a score 3-4 
reveals more severe conditions in which the liver parenchyma shows several fibrotic 
septa, compromised functionality and impaired blood flow, a disease called cirrhosis. 
Other non-invasive and patented tests for the assessment of liver fibrosis are now 
available and they are based on blood indices and imaging modalities (Table 2). 
 
 
Table 2. Selected non-invasive tests to assess liver fibrosis [51]. 
 
Cirrhosis can be classified as compensated or decompensated. Possible clinical 
manifestations of compensated cirrhosis comprise loss of weight and appetite, 
hepatomegaly or/and splenomegaly, high level of serum bilirubin and 
hyperalbuminaemia, although many patients may be symptomless until compensated 
cirrhosis becomes decompensated. Decompensated cirrhosis is defined as a status with 
one of the following symptoms: jaundice, ascites and encephalopathy [48]. For 
assessing the degree of liver disease , The Child-Pugh Score [50] is used. It consists in a 
system to classify the patients as Class A, B or C based on clinical and laboratory criteria 
(Table 3a). Those with class C have the most severe liver disease. 
 
 
Table 3a. Child–Turcotte–Pugh score (Child–Pugh score) [51]. 
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As with any cause of hepatocellular injury, chronic viral infection leads to the 
compensatory proliferation of hepatocytes. This regenerative process is aided and 
abetted by a plethora of growth factors, cytokines, chemokines and other bioactive 
substances that are produced by activated immune cells and they promote cell survival, 
tissue remodeling and angiogenesis. The activated immune cells also produce other 
mediators, such as oxygen species, that are genotoxic and mutagenic. One key 
molecular step seems to be activation of the NF-κB pathway in hepatocytes in response 
to the mediators derived from the activated immune cells. Activation of the NF-κB 
pathway within hepatocytes blocks apoptosis, allowing the dividing hepatocytes to incur 
genotoxic stress and to accumulate mutations. This is the dominant mechanism in the 
pathogenesis of viral-induced HCC. Moreover, HCV also contains proteins within its 
genome that may directly promote the development of cancer, for example, the CORE 
may have a direct effect on tumorigenesis, possibly by activating a variety of growth-
promoting signal transduction pathways. HCC is a primary malignancy of the liver andIt 
is now the third leading cause of cancer deaths worldwide, with over 600.000 new 
cases per year. 
Decompensated cirrhosis and HCC are the main cause of liver transplantation, without 
which the possibility to survive are drastically reduced (survival of 5 years is reduced to 
50%) [52].  
In addition, disease associated with HCV infection is not confined to the liver. In fact, 
extrahepatic manifestations of HCV include cryoglobulinaemia, glomerulonephritis, 
thyroiditis and Sjögren syndrome, insulin resistance, type 2 diabetes and skin disorders 
such as porphyria cutaneatarda and lichen planus. Persons with chronic HCV infection 
are more likely to develop cognitive dysfunction, fatigue and depression [53]. These 
outcomes may be associated with replication of the virus in the brain; however, the 
causal link between these manifestations and chronic HCV infection is not certain [54]. 
 
COINFECTIONS 
 
Because of shared routes of transmission, persons infected with HCV may have 
simultaneously an infection of another pathogen. The main known coinfection is 
HIV/HCV. Certain groups, in particular people who inject drugs, have high rates of this 
coinfection; however there are no reliable estimates of the global prevalence. One 
analysis indicates that 2,3 million persons may be coinfected globally, while an analysis 
from Africa estimated that 5,7% of persons with HIV were coinfected with HCV [40,41]. 
Secondly, in countries as Asia, sub-Sahara Africa and South America the coinfection of 
Hepatitis B virus (HBV) and HCV is commonly observed, where up to 25% of HCV 
infected persons may have HBV.Finally, it is worth elucidating also that groups at high 
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risk of HCV infection are also at high risk of infection with tuberculosis (TB) [42], as TB is 
endemic in many countries where blood products are not screened routinely. In 
particular, people who inject drugs are more at risk of developing TB, regardless also of 
their HIV status and among them, two out of three will have anti-HCV antibodies. 
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1.3. THE IMPORTANCE OF HCV GENETIC VARIABILITY 
 
1.3.1 CLASSIFICATION: GENOTYPE, SUBTYPE AND QUASISPECIES 
 
As abovementioned, the high error rate of RNA-dependent RNA polymerase, which 
lacks proofreading activity, and the pressure by the host system, have driven the 
evolution of HCV into at least 7 viral variants, which diverge each other for the 
genotype, and more than 80 subtypes (Figure 1, paragraph 1.2). The 7 HCV genotype 
groups show a difference each other of a 30-35% of nucleotide sites, otherwise for 
every genotype the RNA sequence homology of the subtypes is about 75-80% (Table 
3b). This major genetic variability is concentrated in the sites encoding membrane 
protein, as E1 and E2 glycoprotein, to guarantee viral spread among different hosts, 
whereas coding sequences of CORE protein and of non-structural proteins, as NS3, are 
highly conserved. Interestingly, 5’ UTR site shows the least variable sequence and this is 
due to its importance for the viral replication [13]. Moreover, the high mutation rate of 
HCV generates the production of a large number of different but closely related viral 
variants during the infection, usually referred to as quasispecies. The fittest of these 
newly generated variants are continuously selected in the environment in which the 
virus replicates, on the basis of their own replication capacities and numerous selection 
pressures, particularly the host immune responses. At a given time point during 
infection, the HCV quasispecies distribution reflects the balance among continuous 
generation of new variants, the need to conserve essential viral functions, and positive 
selection pressures exerted by the replicative environment. 
 
 
Table 3b. Terminology commonly used in studies related to HCV genomic heterogeneity. a% Nucleotide 
similarity refers to the nucleotide sequence identities of the full-length sequences of the HCV genome 
[105]. 
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1.3.2 CLINICAL IMPLICATIONS 
 
The enormous genetic HCV diversity together with some host factors has made it 
difficult to control viral dispersal. Originally, the extent of genetic heterogeneity of HCV 
was not fully appreciated. However, the breadth of the genetic heterogeneity of HCV is 
great, and this has important implications in diagnosis, pathogenesis, treatment and 
vaccine development.  For example, the genetic heterogeneity of the HCV quasispecies 
acts as an epidemiologic marker since it entails the evasion of the host immune system, 
making the infection persistent. Furthermore, the genetic heterogeneity may influence 
the sensitivity and specificity of the serologic and virologic assays for the detection of 
HCV (see paragraph 1.5).  
Secondly, several studies show that the HCV genotype-subtype plays a role in the liver 
disease progression acting together with other cofactors such as viral load, alchol intake 
and length of time of HCV infection. In particular, in patients with chronic HCV, infection 
with genotype 1b is reportedly associated with a more severe liver disease and a more 
aggressive course than is infection with other HCV genotypes [106, 107]. Moreover, 
liver transplantation recipients with HCV genotype 1 have the highest risk of advanced 
fibrosis and lowest sustained virologic response rate [108]. 
In addition, the HCV genotype-subtype is one of the main prognostic factors for the 
choice of the best fitted antiviral therapy for the infected patient. As detailed in 
paragraph 1.4 (Treatment of HCV infection), the HCV genotype was a strong indicator 
for an ineffective therapy: for example, genotype 1 infection was poorly treated with 
IFNα therapy. With the introduction of the new Direct Antiviral Drugs (DAAs), the idea 
of a unique treatment for all genotype was born: in fact, these new drugs aim at having 
an antiviral action against more genotypes as possible, also acting in combination each 
other. Despite the good premises, this pangenotipyc regimen is not completely reached 
yet, resulting in a better response of the DAAs in respect of determined genotypes than 
others. Consequently in the clinical routine the HCV genotype information, together 
with other host conditions (alchol intake, HCV coinfections, renal and liver function, 
drug-drug interactions, Figure 7a) is still require to determine the best antiviral 
treatment. 
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Fig. 7a. Adapted from WHO guidelines 2016; patient treatment pathway [51]. 
 
Finally, there are other aspects regarding the virus that may influence the response to 
the therapy: point mutations in different regions of the viral genome may determine 
the insurgence of resistance to the antiviral treatment and hence influence negatively 
the therapeutic outcome. This genetic barrier, defined as the number and nature of 
nucleotide changes required to confer resistance, is called also RAVs (Resistance 
Associated Variants). The most important RAVs is Gln80Lys variant (Q80K), which is 
highly fit and found in genotype 1a (argument deepened in the following paragraphs). 
Furthermore, data indicate that baseline RAVs are more important as a regimen is 
stressed, for example, when therapy is shortened or more difficult populations are 
treated, and suggest that longer duration of therapy might overcome the influence of 
baseline RAVs [70]. 
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1.4. TREATMENT OF HCV INFECTION 
 
1.4.1 INTRODUCTION: THE IFNα ERA AND THE NEW GENERATIONS OF 
DIRECT-ACTING ANTIVIRAL DRUGS 
 
In the decades following the discovery of HCV, the treatment of infected persons 
became possible. In particular, the purpose of the therapy is to eradicate the virus in 
the patients with chronic infection, in order to prevent cirrhosis and its complications 
and to improve their quality of life.  
The first treatment for HCV was based on a monotherapy of interferon-alpha (IFNα), 
which derives from the cytokine released by host cells in the presence of a pathogen. 
When administered by subcutaneous injection, it inhibits the replication of HCV and it 
modulates the immune response against liver infected cells [56]. Hereafter, Ribavirin 
(RBV) was added to use in combination with IFNα, in order to increase the cure rates. 
The RBV is a synthetic structural analogue of the guanosine, which explicates an 
antiviral activity through different mechanisms of action not yet completely 
understood. For example, it has been proposed that RBN modulates the Th1/Th2 
lymphocyte balance, it inhibits the IMPDH (Inosine Monophosphate Deydrogenase 
Enzyme), or it has a direct inhibitory effect on the viral NS5B, it may introduce lethal 
mutagenesis on the HCV RNNA or finally it impairs the translation via eIF4E inhibition 
[103]. More recently, because of the short half-life of the IFNα after parenteral 
injection, new formulations of IFNα were developed: PEG-IFNα2a, which is IFNα2a 
conjugated to a branched a 40kD PEG molecule, and PEG-IFNα2b, which is IFNα2b 
conjugated to a linear 12kD PEG molecule. These PEG-formulations act similar to the 
standard IFNα but they present slower adsorption, lower enzymatic degradation and 
slower clearance. A systematic review was conducted to assess the efficacy of PEG-
IFNα/RBV versus IFNα/RBV in treatment-naïve adults and children with chronic HCV 
infection. Outcomes assessed were SVR, decompensated liver disease, HCC, all-cause 
mortality, adverse events and quality of life. The available evidence indicated that the 
use of PEG-IFNα/RBV was more effective at achieving SVR compared with the standard 
IFNα/RBV [98]. For these reasons, the dual therapy of PEG-IFNα/RBV has been identified 
for several years as the gold standard therapy [57]. Although PEG-IFNα/RBVshowed 
good performances, it was anyway efficient for the 80% of patients with genotype 2-3 
infection but for fewer than 50% of patients with genotype 1 infection. Moreover, it 
was associated to severe side effects affecting the central nervous system (such as 
headache, neuropathy and depression), the growth and the development of children 
(slowdown) andthe cardiovascular system. Furthermore, acute hypersensitivity 
reactions have been observed (urticarial and bronchoconstriction), as well as thyroid 
abnormalities (both hypo- and hyper-) or ophthalmic disorders (retinal hemorrhage or 
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occlusion of retinal vessels) and more commonly pyrexia, mental disorders and 
hypotension due to fluid depletion. Finally, it was verified that a low efficiency of the 
interferon-based therapy could be due to a high presence at baseline of ISG proteins 
(Interferon Stimulated Gene), which was found more commonly in patients with 
genotype 1 and 4 infection [102].Further, the presence of anti-IFN antibodies developed 
during the treatment may interfere with regimen efficacy. 
A dramatic improvement in HCV therapy have followed the introduction of oral 
medicines that directly inhibites the replication cycle of HCV. Their development was 
achievable as a result of the greater comprehension of the HCV fisiopathology (Fig. 7b). 
These medicines, called Direct-Acting antiviral (DAAs), are shorter in treatment 
duration, they entail fewer side effects and they lead to higher SVRs rather than the 
PEG-IFNα/RBV therapy. 
The first-generation marketed DAAs were coadministered with PEG-IFNα and RBV but 
they were effective only in treating patients infected with HCV genotype 1, moreover 
they might cause several severe side effects, in particular among persons with advanced 
liver disease [56]. The second-generation DAAs have higher rates of SVRs, they are safer 
and they can be used in combinations each other, obviating the need for PEG-IFNα and 
RBV. These combinations have demonstrated a good efficacy in general, although cure 
rates among certain patient subgroups remains lower [59]. 
 
 
Fig. 7b. HCV life cycle and possible molecular targets for the antiviral therapy [58] 
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1.4.2 DIRECT ANTIVIRAL AGENTS: AN IMPORTANT BREAKTHROUGH 
 
1.4.2.1 CLASSIFICATION AND MECHANISMS OF ACTION 
 
Understanding the mechanisms of action of the DAAs as well as related issues, including 
the molecular basis for resistance, helps to guide drug development and clinical use. 
Several reviews have described how insights into the viral life cycle have facilitated the 
development of DAAs [63,64]. To date, inhibition of HCV replication has focused on 
three major viral targets: the NS3/4A, the NS5B and the NS5A. 
Protease inhibitors (PIs): The HCV NS2 and NS3 are both proteases with well-
characterized enzymatic activities, making them logical targets for pharmaceutical 
intervention strategies. In spite of efforts to develop inhibitors of NS2 and NS3, only 
compounds that target NS3 have advanced in clinical use. Ciluprevir (BILN-2061) was 
the first HCV PIs which advanced in clinical trials [65] but it was stopped because of its 
severe toxic effects. Although the failure, these studies validated NS3 as a therapeutic 
target. Furthermore, available crystal structure of NS3 in complex with candidate 
compounds showed that most interactions are mediated via the protease domain, 
whereas weak contacts happens with the helicase region [66]. Boceprevir (BOC) and 
Telaprevir (TVR) are an example of drugs that react with the catalytic site of the 
protease domain and they were approved in 2011, representing the first class of DAAs 
successfully used in the clinic. Although these first-generation PIs stand for a major 
advance in the treatment of HCV, they have several limitations, including narrow 
genotype specificity and a low barrier to resistance. Moreover, there are several 
possible mutations (RAVs) in the NS3, which lead amino acid substitutions conferring 
drug resistance (Table 5). Other compounds, which belong to the second wave of the 
first-generation PIs, include Simemprevir (SIM), Paritaprevir (PTV) and Asuneprevir 
(ASV), but they have similar limitations of the first wave. Conversely, the second 
generation of PIs, comprising Grazoprevir (GZR), aim at a more pangenotypic activities 
that reduce viral escape through common RAVs of the first-generation PIs [67].  
What is more, studies show that PIs have an additional indirect effect on HCV: PIs 
therapy restores TLR3 and DDX58 signalling, leading to endogenous IFN production and 
its associated antiviral activity [68]. 
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Table 5.  Profile of PIs [67]. 
 
NS5B inhibitors: Clinically relevant NS5B inhibitors can be classified into non-nucleotide 
inhibitors (NNIs) and nucleotide inhibitors (NIs) that act at distinct stages of RNA 
synthesis [69]. 
NNis interfere through a non-competitive mechanism with the conformational 
dynamics of NS5B at its transition from initiation to elongation process. In particular, 
different classes of NNIs can bind to distinct regions in the ‘thumb’ subdomain (‘thumb’ 
sites I and II). ‘Thumb’ site I inhibitors comprise compounds with a benzimidazole or 
indole scaffolds, such as Beclabuvir, whereas ‘thumb’ site II inhibitors have thiophene-
based structures, such as GS-9669. Unfortunately, compared to NIs, NNIs have 
limitations in their antiviral effectiveness (67). In addition to these classes of inhibitors, 
there are other compounds that interfere with the ‘palm’ subdomains, which is a 
hydrophobic area in close proximity of the active site. These ‘palm’ site inhibitors might 
affect RNA synthesis through interference with nucleotide incorporation at the level of 
initiation [70]. Usually, these inhibitors comprise a benzothiadiazine scaffold, such as 
Dasabuvir (DSV). Comparatively to PIs, NNIs have different RAVs (Table 6). 
NIs interfere through a competitive mechanism with the incoming nucleoside 
triphosphate for the binding and the incorporation process. They are usually 
administrated as prodrugs that require metabolic activation to the triphosphate form 
that is eventually accommodated at the nucleotide-binding site of NS5B (70). The main 
NIs is Sofosbuvir (SOF), which is a phosphoramidateprodrug that is ultimately activated 
inanuridine analogue. Compared to NNIs, NIs commonly show pangenotypic activity 
with a higher barrier to resistance (Table 6). 
 
Table 6.  Profile of NS5B inhibitors [67]. 
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NS5A inhibitors: NS5A inhibitors show exceptional potencies due to the involvement of 
this protein at various stages in the viral life cycle, particularly in the replication and the 
assembly. Probably, the most important passage is the inhibition of the formation of the 
virus-induced membranous web that provides the site for the viral replication [70]. The 
first NS5A has been Daclatasvir (DCV), which is a symmetric dimeric molecule that may 
compete with viral RNA such that a dynamic equilibrium occurs between NS5A dimers 
that bind either RNA or the drug [71]. Ledispavir (LDV) and Ombitasvir (OMV) are 
related compounds also approved for clinical use [72]. Elbasvir (EBR) and Velpatasvir 
(VPV) are NS5A inhibitors of a second generation and they show potent broad genotype 
antiviral coverage than the first generation (Table 7). 
 
Table 7.  Profile of NS5A inhibitors [67]. 
 
1.4.2.2 CONTRAINDICATIONS: DRUG-DRUG INTERACTION 
 
The emergence of data regarding the use of DAAs has resulted in a broader 
understanding of the complex DDIs. DDIs entail that drugs have to be used in 
combination with extremely caution which results in a dose adjustment, altered timing 
of administration, additional monitoring or in a contraindicated administration.  
Some DAAs as SIM, PTV, DCV, ZEPATIER regimen, and in part also OMB and DSV are 
extensively metabolized by the cytochrome (CYP) 3A4 system. Therefore, substances 
that are moderate or strong inducers or inhibitors of CYP3A4 are not recommended as 
these may led to significant respectively lower or higher exposure of the DAAs.  These 
substances may include anticonvulsants (such as carbamazepine, oxcarazepine, 
phenobarbital and phenytoin), antibiotics (such as erythromycin, clarithromycin and 
telithromycin), antimycobacterials and systemically administered antifungals (such as 
rifampin and fluconazole respectively) and a great number of antiretroviral drugs (such 
as HIV protease inhibitors). Moreover, dose adjustments are needed with some 
antiarrhytmics, warfarin, calcium channel blockers, HMG Co-A reductase inhibitors and 
sedative/anxiolitics. Other CYP involved in the metabolism of the DAAs are CYP2C8 and 
CYP1A2-1B3: CYP2C8 is the main metabolizer of DSV and CYP1A2-1B3 is engaged 
minimally with SIM.  
In DAAs pathways, moreover, the transport proteins are interested. Some DAAs such as 
SOF, LDV, DVC, PTV and DSV are transported by P-gp (P-glycoprotein) and BCRP (Breast 
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Cancer Resistant Protein), and therefore any co-administered drugs that are potent P-
gp and BCRP inducers will decrease DAAs plasma concentration, leading to a reduced 
therapeutic effect. Whereas co-administration with drugs that inhibit P-gp and BCRP 
may increase the exposure of DAAs though clinical consequences are unlikely. Some P-
gp substrates are digoxin and dabigatran, cyclosporines and more over. Another 
important transporter is OAT1B1/B3 whose substrates are SIM, DCV and PTV. 
Finally, other significant known DDIs concern SOF: if co-administrated with Amiodarone 
in combination with another DAA may result in serious symptomatic bradycardia. The 
mechanism for this DDI is poorly understood and it reported to have caused one fatality 
due to cardiac arrest [94]. Moreover, OMB, PTV and DSV may have numerous DDIs in 
combination with Ritonavir. 
In conclusion, a comprehensive DDI programme should be consulted prior to treatment 
initiation [93]. The regulatory guidance of both EMA and FDA and other guidelines for 
example of EASL supply specific details on DDIs fot he anti-HCV therapy. Moreover, the 
WHO suggests to consult the University of Liverpool webpage on hepatitis drug 
interactions (http://www.hep-druginteractions.org/) [51]. 
 
1.4.2.3 CLINICAL DATA 
 
VIROLOGICAL RESPONSE 
 
To better understand the clinical data about the DAAs regimens, it is important to 
define the so-called virological response. The viral kinetics represents an important 
parameter to monitor the response to the therapy over time. In fact, the HCV RNA 
decline during the treatment is highly associated to the achievement of a good 
therapeutic response. HCV RNA is measured at specific times before, during and after 
the treatment: in particular at baseline, at weeks 4 and 12, at the end of the treatment 
(week 24 or 48 depending on the duration of the therapy) and then 24weeks after the 
end of the treatment (that is at week 48 or 72) (Fig. 8). 
 
 
 
 
Fig. 8. Times of HCV RNA detection. 
Each specific time of HCV RNA detection coincides with a parameter called virologic 
response, which is critical to determine the efficacy of the therapy (Fig. 9). In particular, 
Baseline Follow-up Treatment 
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at week 4 and 12 Rapid Virologic Response (RVR) and extended RVR (eRVR) or Early 
Virologic Response (EVR) are respectively evaluated, whereas at the end of the 
treatment End-of-Treatment Response (ETR) is estimated and finally 24 weeks later 
Sustained Virologic Response (SVR) is determined. 
Overall, the gold standard criterion indicating a successful therapy is the achieving of 
the SVR. SVR can be detected also 12 weeks (SVR12) after the treatment. It is known 
that the infection is cured in more than 99% of patients who achieve an SVR [93], in 
fact,a systematic review shows as in analyses of SVR durability, the incidence of late 
relapse is extremelylow (1%) [61]. Moreover, histologic regression of both 
necroinflammation and fibrosis has been demonstrated in paired liverbiopsy samples in 
SVR-achieving patients, who have significantly fewer liver-related complications, less 
hepatocellular carcinoma, and fewer liver-related deaths than non-responders or those 
untreated [61]. 
On the other end, the absence of EVR is predictive of a failed treatment: in fact the 99% 
of patients who do not achieve EVR, they do not even accomplish SVR [62]. 
 
 
Fig. 9. Rapid virologic response (RVR): undetectable hepatitis C virus (HCV) RNA at week 4. Extended RVR (eRVR): HCV 
RNA <10-15 IU/ml at weeks 4 and 12. Early virologic response (EVR): ≥ 2 log 10 reduction from baseline HCV RNA, but 
virus remains detectable (partial EVR) or is undetectable (complete EVR) at week 12. Early responders: HCV RNA <10-
15 IU/ml at week 8. Partial response: ≥ 2 log 10 reduction from baseline HCV RNA at week 12, but virus remains 
detectable through week 24 or treatment end. Breakthrough: undetectable HCV RNA during treatment followed by 
appearance of HCV RNA, despite continued treatment. End-of-treatment response (ETR): undetectable HCV RNA at 
the end of treatment. Sustained virologic response (SVR): undetectable HCV RNA at 24 weeks after treatment 
completion. Relapse: undetectable viremia during treatment and/or at the end of treatment, but subsequent viremia 
following treatment cessation. Non-response: detectable circulating HCV RNA throughout treatment. Null-response: 
<2 log 10 reduction from baseline HCV RNA during the treatment è [60]. 
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IFNα-BASED DAAs REGIMENS 
 
DAAs regimens have been approved for anti-HCV therapy starting from 2011, when the 
first-generation of PIs, TVR and BOC, were approved in combination with PEG-IFNα/RBV 
[www.fda.gov]. Although this triple therapy represented a step forward compared to 
the conventional IFNα therapy, it was associated to severe adverse effects. In fact, 
currently the treatment guidelines do not recommend it [51]. Although with the 
introduction of DAAs the treatment for HCV infection is moving away from the use of 
interferon, PEG-IFNα/RBV is still recommended in some cases; in fact, it is used in 
combination with some of the second wave of first generation PIs, such as SIM, SOF and 
DCV. The phase III of QUEST-1/2 trials shows that SIM plus PEG-IFNα/RBV for 12 weeks 
followed by PEG-IFNα/RBV for 12 or 36 weeks according to criteria for response-guided 
therapy results in  SVR of 80 to 81% of treatment-naïve patients with genotype 1 
infection [74,75]. However, a new issue arose: the importance of baseline RAVs: the 
Q80K viral polymorphism, which is estimated to be present in the 48% of untreated 
patients with genotype 1a infection [76], reduces the rates of SVR similar to those 
treated with PEG-IFNα/RBV alone (~58%). Finally, clinical trials point out that the rate of 
SVR in triple therapy including SIM is 83% in previously untreated patients with 
genotype 4 [77]. 
The most potent IFNα-based DAA regimen appears to be the triple therapy with SOF. In 
the phase III of NEUTRINO trial, a 12-week regimen of SOF plus PEG-IFNα/RBV results in 
a SVR of 92% in previously untreated patients with genotype 1a, 82% in those with 
genotype 1b, 96% in those with genotype 4 and moreover one patient with genotype 5 
and all six patients with genotype six show SVR [78]. Recently, data from the BOSON 
study have suggested that this triple therapy may have an active role also in the 
treatment of cirrhotic patients with genotype 2-3 infection [79]. 
Similarly, DCV has been investigated in IFNα-based regimens for patients with genotype 
1 and 4 infection. The phase IIb of COMMAND-1 trial indicates that DCV plus PEG-
IFNα/RBV for 12 weeks followed by PEG-IFNα/RBV for 36 weeks yields a SVR in 55% of 
previously untreated patients with genotype 1a, 77% of those with genotype 1b and 
100% of those with genotype 4 [80]. Besides, the recent addition of ASV to this regimen 
increases the SVR rates to over 90% in cirrhotic patients with genotype 1 and 4 infection 
[81]. 
Notwithstanding, the IFNα-based regimens are no longer recommended in the 
guidelines, at least as first-line therapy for treatment-naïve patients, because they are 
inferior to IFNα-Free oral DAAs combinations in term of both safety and tolerability 
profiles. 
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IFNα-FREE DAAs REGIMENS 
 
The era of IFN-Free DAAs regimens promises a revolutionary change in the therapeutic 
options for those in most need of HCV eradication. These regimens are well tolerated, 
with low rates of serious adverse events or discontinuation of therapy [82]. The first 
IFNα-Free regimen to achieve a SVR comprised the combination of ASV and DCV for 24 
weeks [83]. Data of IFNα-Free DAAs treatments regard predominantly patients with 
genotypes 1, 2 and 3, whereas there are limited data for genotypes 4 and 6.  A 
systematic review summarizes the significant trials of IFNα-free DAA regimens 
according to genotype 1-4 [84] (Tables 1 and 2 of Appendix 2).  
To sum up, several combinations of DAAs with different mechanisms of action and 
levels of genetic barrier are proved. Moreover, the inclusion of RBV and Ritonavir, a PI 
for anti-HIV therapy, has also evaluated. Clinical trials confirm that the addition of RBV 
to the drug regimen betters the number of patients who reach a SVR [85]. This aspect 
may due to the importance of RBV for reducing the incidence of and delaying the 
emergence of genetic barrier; however, the mechanisms underlying its effects remain 
unclear [86]. Secondly, it appears from trials that often the increase in the duration of 
the treatment (from 12 weeks to 24 weeks) may improve SVRs [87,88]. Another 
important point is that naïve patients, in other words patients who have not already 
received a treatment before, are usually more responsive than patients with an already 
treatment-experience. Moreover, patients with genotype 3 infection draw less benefit 
from these regimens than others infected with other genotypes [84]. 
Finally, a small number of pangenotypic regimens have been studied in the 
decompensated-cirrhotic population, with the majority of data arising from the pre-
Liver-Transplantation (LT) setting. For these patients awaiting LT, the primary aim of the 
therapy is to prevent recurrent HCV infection of the new liver, which is associated with 
reduced graft and patient survival [89]. A systematic review summarized these data [84] 
(Table 3 in Appendix 2).  
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Fig. 11. Treatment of HCV with DAAs that are approved or that are going to be approved [67]. 
 
MONITORING FOR ADVERSE EVENTS 
 
Monitoring guidance for the detection of adverse events to HCV treatment has largely 
been based on the experience PEG-IFNα/RBV therapy. Newer DAAs regimens are much 
better tolerated by patients, as they have fewer adverse events and thus less need for 
early discontinuation of therapy. Therefore the frequency of routine laboratory 
monitoring may be reduced; however, there remains the need for laboratory 
monitoring in patient with cirrhosis or renal impairment, HIV coinfection, potential DDIs 
and who are treated in combination with PEG-IFNα/RBV. The WHO supplies a summary 
framework for the monitoring of the adverse events in these patients [51].  
Despite the main side effects of DAAs regimens may comprise fatigue, headache, 
nausea and sometimes anemia, some cases of severe adverse events were observed: 
studies on NIs demonstrate that if NIs are incorporated by host RNA or DNA 
polymerases, severe toxicity might ensue, aspect that led the development of many 
promising agents in this class being halted [72]. Moreover, possible hepato-toxicity have 
emerged in patients with decompensated cirrhosis treated with SOF [91].  Similar data 
are obtained in a study in which seven of 160 patients treated with SOF plus LDV and 
Ribavirin died during therapy in the pre-LT or post-LT setting: subtle hepatic and/or 
systemic toxicity due to DAAs regimen cannot be excluded as cause of death [92]. 
Finally, it has been recognized also that SOF might cause cardiotoxic effects. 
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1.4.2.4 STATE OF ART 
  
Advances in drug development and the availability of a wide range of clinical trials are 
revolutionizing HCV treatment. Each year the Food and Drug Administration (FDA) and 
the European Medicines Agency (EMA) approve several DAAs regimens. The approved 
DAAs, by both FDA and EMA, to date are listed in Table 7b. 
 
 
Table 7b. Approved anti-HCV drugs in 2016. 
 
In addition to these, the VIEKIRA PAK is approved and it consists in the combination of 
TECHNIVIE with EXVIERA. 
Because of the great availability of DAAs and their use in combinations, several 
guidelines are prepared, which serve as a guide for persons managing hepatitis 
treatment programmes and clinicians. These guidelines are defined by a chosen panel 
of experts and they supply evidences and recommendations for the screening, the care 
and the treatment of persons with HCV infection. The recommendations are formulated 
using a grading system that consists usually in an adaptation of the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) method. This is a 
method that provides guidance and tools to define research questions, to develop an 
analytical framework, to conduct systematic reviews, to assess the overall quality of the 
evidence and to determine the direction and strength of the recommendations [51].  
In Appendix 3 (Table 5 and 6), the treatment recommendations written by the 
European Association for the Study of the Liver (EASL) are reported. These 
recommendations elucidate the regimens and the durations of anti-HCV treatment to 
be used according to the HCV genotype and the clinical outcome of the patient. The 
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DAAs approved in 2016 (ZEPATIER and EPCLUSA) are not integrated yet in the 
recommendations, and their indications of use are listed below (Table 8). 
 
 
 
 
 
 
  
 
Table 8. Approved anti-HCV drugs in 2016 Zepatier and Epclusa. Epclusa s indicated for the treatment of 
adult patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection (Prescribing Information Taken by 
FDA). 
 
Finally, other guidelines are available formulated by the World Health Organization 
(WHO) [51], the Associazione Italiana per lo Studio del Fegato (AISF) [95], the American 
Association for the Study of Liver Disease (AASLD) in collaboration with the Infection 
Disease Society of America (IDSA) [96], and the US Department of Veterans Affair [97], 
and others. 
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1.5. DIAGNOSIS OF HCV INFECTION 
 
Today, the laboratory diagnosis of HCV infection is extremely reliable thanks to available 
assays capable of identifying persons infected with a sensitivity and a sensibility near to 
100%. The diagnosis of HCV infection is essentially based on the positivity of anti-HCV 
antibodies and on the increase of transaminases (in particular ALT). Considering that the 
onset of the disease is usually asymptomatic, the identification of the infection is usually 
casual or following screening test for anti-HCV antibodies (for surgeries, subjects at risk, 
blood donations, etc.) or also in case of a casual finding of hypertransaminasemia.  
The diagnostic assays for the diagnosis and management of HCV infection include two 
classes: indirect assays that evaluate the antibody response to viral antigen (anti-HCV, 
RIBA) and direct assays that detect the presence in serum of the viral genome 
(qualitative or quantitative HCV-RNA) or of a viral antigen (such as core antigen). Over 
the past 15 years, the diagnostic assays underwent considerable progresses: the 
availability of more sensitive and accurate methods and the introduction of automated 
equipment in clinical diagnostic, allow to perform multiple tests in a short time and to 
support high workloads to confront with the routine need of the laboratory. 
 
1.5.1 INDIRECT ASSAYS 
 
Serologic assays detect HCV specific total antibodies (IgM and IgG) and they are used to 
screen and diagnose HCV exposure. Anti-HCV antibodies are revealed thanks to a 
capture antigen (usually recombinant) which is specific of viral regions and hence the 
binding antigen-antibody can be detected through different techniques. Over times, 
serologic assays evolved from a first to a third generation of tests depending on the 
number and the type of capture antigens involved. In 90s, the first generation assays 
used as the capture antigen the recombinant C100-3 (from NS4 viral protein), whereas 
the second generation assays detected antibodies against CORE (recombinant capture 
antigen C22-3) and NS3 and NS4 (capture antigen C200). To date, the third generation 
assays have reached a specificity and a sensibility of more than 99%. These tests (anti-
HCV 3.0) are capable to identify antibodies against CORE (capture antigen C22-3), NS3 
and NS4 (capture antigens C33-C, C100-3, C200) and, for more, NS5 regions. 
Serologic assays can be used as screening assays or confirmatory methods.  
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SCREENING ASSAYS 
 
The screening assays are based on the detection of anti-HCV antibodies through a 
simple enzyme immunoassay (EIA) and they are entailed in multiple uses. For example, 
they are used for studies of prevalence and incidence of HCV infection in the general 
population or for the screening of categories of subjects at risk (such as people who 
inject drugs, hemophiliacs, people undergoing dialysis or transplantation etc). In EIAs, 
the binding antigen-antibody is indicated through a colorimetric reaction but to date, 
new versions of signal detection based on fluorescence and chemiluminescence (cLIA: 
ChemiLuminescent ImmunoAssay) techniques are available. Moreover, new 
immobilization methods for the capture antigens are available: MEIA (Microparticle 
Enzyme ImmunoAssay) and CMIA (Chemoluminscent Microparticle ImmunoAssay). The 
screening assays produce quantitative results and the criteria for interpreting them are 
generally based on the calculation of a value cut-off/ratio as recommended by the 
company that produced and marketed the tests. The table 9 elucidates some of the 
screening assays currently on the market. 
Despite the good performances of the actually used third generation EIAs, even among 
a population with a low prevalence of infection, a specificity of 99% does not guarantee 
that there may be false positives. In immunocompetent persons with a prevalence of 
anti-HCV antibodies less than 10% (such as  blood donors, military, general population, 
health professionals or subjects afferent to a clinic for sexually transmitted diseases), 
the rate of false positive results can also reach the 35%; whereas in 
immunocompromised subjects (for example persons undergoing dialysis) it can arrive at 
15%. For this reason, a positive result in a screening assay should be verified through a 
supplementary confirmation test with high specificity (confirmatory methods).  
 
 
Table 9. Example of screening assays. The specificity and the sensitivity values refer to the brochure of 
the kit. 
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CONFIRMATORY ASSAYS 
 
The confirmatory assays are tests of third generation based on the principle of 
immunoblot on strip (RIBAs, Recombinant ImmunoBlot Assays) and they are used to 
confirm the presence of HCV specific antibodies for individuals who have tested positive 
by the screening assays. The results of these RIBA are interpreted as positive, 
undetermined or negative depending on the number of bands present on the strip 
(parameter recommended by the company that produced the test). A positive result is 
explained as positive for HCV infection even if it is not possible to distinguish between 
an active and a resolved infection, hence a HCV-RNA assay should be performed. A 
negative result is interpreted as negative for HCV infection and it indicates a false 
positive from the screening assay. Rarely, negative results for anti-HCV both in 
screening assays and confirmatory assays were observed in cases of acute infection 
with late seroconversion to anti-HCV antibodies or in cases of HCV infection resolved 
with an antibody titer below the detection limit of the assays. Occasionally, 
immunocompromised subjects resulted both EIA and RIBA negative are positive for 
HCV-RNA [99]. Finally, an undetermined result reveals a screening assay not estimable. 
In particular, it indicates a false positive screening assay, with a probability of 1-2% in 
blood donor, <5% in the general population, 4-5% in health workers and 10% in people 
undergoing dialysis [99]. In the clinical practice, a subject with an undetermined RIBA 
should be rechecked after at least one month and in case of another undetermined 
result, HCV RNA assays should be done. Moreover, undetermined results from 
confirmatory assays have been observed in subjects with a recent infection in 
seroconversion phase or occasionally in persons with a chronic HCV infection [99]. The 
table 10 elucidates some of the confirmatory assays currently on the market. 
 
 
Table 10. Example of confirmatory assays. The specificity and the sensitivity values refer to the brochure 
of the kit. 
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1.5.2 DIRECT ASSAYS 
 
The detection of viral components is needed to diagnose an active HCV infection. Direct 
methods include molecular HCV assays and quantification of HCV Core antigen.  
 
MOLECULAR ASSAYS 
 
The molecular assays or NAT tests (Nucleic Acids Testing) determine the presence of the 
viral nucleic acids (HCV-RNA) in serum or plasma samples and they are used to confirm 
the diagnosis of active HCV infection in subjects with the positive serological-
confirmatory assays. An active HCV infection can be early revealed because the HCV-
RNA can be detected before specific antibodies become appreciable (within 1-3 weeks 
after exposure). Moreover, NAT tests are required for confirm a chronic HCV infection 
by the presence of both anti-HCV antibodies and HCV-RNA over 6 months after the 
exposure [100]. 
The highly conserved 5’UTR region is the target of choice for the HCV genome 
detection. The research of HCV-RNA can be carried out with both qualitative and 
quantitative assays. These assays are based on different techniques, such as reverse 
polymerase chain reaction (RT-PCR), transcription-mediated amplification (TMA), 
branched DNA assays (bDNA) and more recently the amplification in real time of the 
viral HCV-RNA (Real Time PCR). The choice to use a qualitative or a quantitative assay 
depends on the clinical context. For example, during the anti-HCV treatment, the 
evaluation of the SVR requires a qualitative test, whereas before starting the therapy 
and at 12 weeks for the evaluation of EVR a quantitative assay is necessary [99]. To 
date, Real Time PCR assays allow, in the same session, to determine the presence and 
contemporaneously to quantify the HCV-RNA (in a dynamic range from 30 to 108 UI/ml) 
and it becomes the reference method for the quantification of HCVRNA levels in clinical 
practice according to European and American guidelines. The table 11 lists some of the 
confirmatory assays currently used in clinical practice. 
Regarding the interpretation of the results, a negative HCV-RNA result is not fully 
representative of a resolved infection indeed the viral replication during an infection is 
usually intermittent:  a negative HCV-RNA result explains a resolved infection in the 15-
25% of subjects who become infected in adulthood an in the 40-45% of children and 
youth population [99]. For this reason, the evaluation of HCV-RNA over time is 
recommended to have more decisive data.  
In addition, starting from 2002 in Italy, NAT tests for the screening of blood donors have 
been introduced, aiming at minimize the risk of HCV transmission through blood 
transfusions.  
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Table 11. Example of NAT assays. The analytical sensitivity and range values refer to the brochure of the 
kit. 
 
HCV CORE ANTIGEN DETECTION ASSAYS 
 
The HCV Core antigen detection and quantification is based on the detection of the 
CORE antigen in the serum of the patients and its levels are significantly related to those 
of HCV-RNA [101].  HCV Core assays could be used in alternative of the HCV-RNA assays 
for three different conditions: to distinguish active from resolved HCV infections; to 
identify HCV infection in the antibody window period; to identify HCV infection in 
seronegative individuals at high risk for HCV infection, such as patients undergoing 
dialysis.  
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Fig. 12.  Scheme of the recommended testing sequence for identifying current HCV infection [96]. * For 
persons who might have been exposed to HCV within the past 6 months, testing for HCV RNA or follow-
up testing for HCV antibody should be performed. For persons who are immunocompromised, testing for 
HCV RNA should be performed; † To differentiate past, resolved HCV infection from biologic false 
positivity for HCV antibody, testing with another HCV antibody assay can be considered. Repeat HCV RNA 
testing if the person tested is suspected to have had HCV exposure within the past 6 months or has 
clinical evidence of HCV disease, or if there is concern regarding the handling or storage of the test 
specimen. 
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1.5.3 GENOTYPING AND SUBTYPING ASSAYS 
 
Although DAAs therapy aims at a pangenotypic regimen, to date the genotype 
information is necessary before starting the anti-viral treatment; in fact, the current 
recommendations show the DAAs regimen to be adopted depending on the HCV 
genotype. Moreover, for the same reason, also the subtype of the virus is important to 
know. The gold standard for HCV genotyping is the genome sequencing of the NS5B 
region and subsequent phylogenetic analysis; however, this in-house method is 
restricted to reference centers. Therefore, other techniques have become available and 
actually there are many commercial assays for HCV genotyping based on them (Table 
12). These techniques comprise indirect and direct assays that consist in the detection 
of the HCV genotypes respectively with genotype specific antibodies and competitive 
enzyme immunoassays or with direct analysis of specific regions of the viral genome 
through methods as Real Time PCR, RLB (Reverse Line Blot) or Fragment Analysis.  
Over time, the region of choice for the direct genotyping assays has been the highly 
conserved 5’UTR indeed this region allows a well differentiation between several HCV 
genotypes (1 to 7a). Recently it has been recognized that 5’UTR is not sufficient to allow 
the differentiation of genotype 1 from 6 and a good discrimination between subtypes 
1a and 1b. In fact, genotype 1b shares an identical 5’UTR sequence with genotypes 6 
variants (subtypes c to l), furthermore the discover of the existence of clades within the 
genotype 1a allow the recognition of the misdiagnosis between clade I AND II (genotype 
1a) and genotype 1b (Fig. 13) [104]. For these reasons, the guidelines recommends to 
use assays that analyze a second viral region in combination with the 5’UTR.  The two 
regions most frequently chosen for this combined analysis are the NS5b and the CORE 
sequences because they are informative to discriminate subtypes and genotypes 1 to 6, 
but also sufficiently conserved to allow primers annealing. 
 
 
Table. 12.  Example of genotyping and subtyping assays. The notes refer to the brochure of the kit. 
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Fig. 13.  Alignment of the 5’UTR consensus sequences of subtype 1a clade I and II and subtype 1b. At 
position 107 subtype 1a clade I exhibit a G, as subtype 1b, leading to misdiagnosis. Moreover, also the 
usual presence of a C at position 204 in subtype 1a clade II can entail misdiagnosis with subtype 1b, 
where C and T are the most frequent nucleotides in the same position [104]. 
 
Finally, although commercially genotyping assays reached over time higher specificity 
and sensitivity, routine genotyping methods, however, may cause wrong, inaccurate, or 
incomplete assignment in up to 10% of cases, due to indeterminate results, mixed 
infections, wrong subtyping, and even wrong genotyping. In these cases, the samples 
should be retested using either an alternative commercial assay or the reference 
method (NS5b sequencing), increasing the costs of the analyses. 
 
1.5.4 RAVs DETECTION 
  
Although the presence of different RAVs, currently guidelines consider only the Q80K 
mutation testing, which, as abovementioned, is a NS3  polymorphism that reduces the 
efficacy of the treatment with SIM. The presence of Q80Kis associated to the genotype 
1a, and therefore patients with genotype 1a infection need to be tested for the Q80K 
prior to prescribe SIM and to consider an alternative therapy if it is detected. 
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2. AIM OF THE STUDY 
 
As the HCV genotype is a crucial information for the clinical routine, we decided to 
develop a high-throughput system able to supply accurate data about the genotype and 
the subtype of the virus and at the same time to satisfy the requests of the diagnostic 
laboratories. In detail, this work is focused on the design and the validation of a 
standardized and performing process starting from the clinical sample up to the 
genotype and subtype result. Because of the high demand for this type of analysis, we 
chose to develop modular workcells as possible automated, in order to make the 
process fast and simple for the user. As shown in figure 14, these modules consist in:   
1) Automated extraction of viral nucleic acid (HCV RNA) starting from the clinical 
sample;  
2) One step reaction for the retrotranscription and amplification (RT-PCR) of the 
HCV-RNA; 
3) Genotyping of the PCR product. 
 
 
Fig. 14.  Scheme of the modular workcells for the genotyping analysis of HCV. 
 
In the first part of this project I focused on the design and development of an 
automated kit for the extraction of  pathogen nucleic acids. In the second part, I worked 
on the evaluation of the HCV genotyping with the AMPLIQUALITY HCV TYPE PLUS 
device. 
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3. PART I: AUTOMATED EXTRACTION KIT DEVELOPMENT 
 
In the first part of this project I focused on the design and development of an 
automated kit for the extraction of  pathogen nucleic acids. 
 
3.1 MATERIALS AND METHODS  
 
3.1.1 GENEQUALITY X120 
The automated extraction kit has been designed to be used with the GENEQUALITY 
X120 platform, which is a liquid handler developed by AB ANALITICA (Fig.15). This 
workstation has been chosen because it offers an innovative technology for higher 
process reliability, performance, and flexibility. The main peculiarity stands in its air 
displacement pipetting, which guarantees high pipetting accuracy and precision, and in 
the CO-RE system (Compressed O-Ring Exspansion) that attaches disposable tips using a 
highly robust lock-and-key style mechanism, in order to eliminate mechanical stress and 
minimizing the production of aerosols. Moreover, it supplies a series of commands such 
as anti-droplet and aspiration-dispense monitoring controls. The deck of the instrument 
has been configured with two shakers, one of which able to heat, a magnet, a drain for 
the liquid and solid wastes, and a set of carriers for introducing samples, reagents and 
tips. This entire system lends itself to numerous applications, among which the 
possibility to develop a high-throughput extraction process. 
 
 
Fig. 15.  Automated platform GENEQUALITY X120. 
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3.1.2 EXTRACTION PROTOCOL DESIGN 
A nucleic acids extraction is a process for the purification of DNA/RNA from samples 
using a combination of physical and chemical methods. Although different purification 
techniques exist, there are some common steps. The first passage consists in the 
mechanical and chemical breaking of the cell membranes (cell lysis) for the release of 
the nucleic acids. Usually, the cell lysis occurs under continuous thermo-shaking in a 
reagent mainly composed of detergents and surfactants. In addition, a protease is used 
to digest the membrane proteins. After the lysis, the exposed DNA/RNA is purified from 
the other components by different procedures: 
1) Ethanol precipitation: since the nucleic acid is insoluble in these alcohols, it 
aggregates together, giving a pellet upon centrifugation. The precipitation is 
improved by increasing of ionic strength, usually by adding sodium acetate; 
2) Phenol-chloroform extraction: the phenol denatures proteins that after 
centrifugation stay in the organic phase while the aqueous phase containing the 
nucleic acid mixed with the chloroform that removes phenol residues from 
solution; 
3) Adsorption on a solid support: the nucleic acid is bound on a solid phase 
depending on the pH and the salt concentration of the binding buffer. The solid 
phase is commonly composed of silica materials that show a good affinity for the 
DNA/RNA. To enhance this affinity, functional groups can be added. The solid 
phase can be arranged in mini-column or magnetic beads. 
For the development of the automated extraction kit we have chosen the adsorption 
technique because it shows major efficiency than the others in the pathogen nucleic 
acids extraction. In particular we opted  for the magnetic beads since they have more 
affinity than the mini-column and they are the best format to be adapted to the 
GENEQUALITY X120 platform. Once the binding step occurs, the magnetic beads are 
washed several times in order to remove possible contaminants and at the end of the 
process, the DNA/RNA is eluted from the solid phase to a specific buffer. 
Several commercial extraction reagents have been tested in order to choose the best 
performing combination that fitted our purpose. The commercial names of these 
reagents are not reported, in protection of industrial secrecy.  
In addition to these reagents, we thought to provide the extraction kit of internal 
controls (ICs), in order to monitor the presence of inhibitors or other factors that may 
cause false-negative results. The internal controls are in fact used as indicator of a good 
nucleic acid extraction and quality of sample. An IC should be easy to produce and to 
standardize and additionally, It should be stable, noninfectious, and suitable for 
different assays. In particular, we opted for exogenous ICs that are added to the sample 
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before starting the extraction protocol. We decided to supply the kit with an internal 
control for the monitoring of the DNA extraction (IC DNA) and another control for the 
RNA (IC RNA). As regard the IC DNA, a linear plasmid of β-globin has been chosen, 
because it has already been studied in the company, showing good stability and 
extraction performances. Concerning the IC RNA, an E. coli phage has been selected, 
since it is resistant to RNase degradation, even at high storage temperatures and it is 
sufficiently stable for the routine use. The chosen ICs offer the possibility once 
extracted to be downstream evaluated with the pathogen target by different analysis 
techniques (Real time PCR and Reverse Line Blot). 
Finally, a carrier has been added to the extraction kit, which favors the pathogen nucleic 
acids extraction, by co-precipitation. 
 
3.1.3 PACKAGING DESIGN 
A crucial point in the development of the extraction kit has been the selection of the 
packaging to be use in combination with the platform GENEQUALITY X120. Different 
parameters has been evaluated , such as the type of plastics and containers to use, the 
reagents volumes to include and how to seal the components. Several options have 
been tested in order to choose the most stable packaging and to obtain no degradation 
and evaporation of reagents during time. 
 
3.1.4 NUCLEIC ACIDS EXTRACTION WITH BIOROBOT EZ 
The CE IVD instrument BioRobot EZ1 (Qiagen) has been used as reference method for 
the evaluation of our extraction kit. The BioRobot EZ1 DSP System used with the EZ1 
DSP Virus kit (Qiagen) enables automated purification of viral nucleic acids starting from 
different type of samples. The extractions have been performed following the 
manufacturer’s instructions, and adding our Internal Controls to monitoring the 
extraction efficiency (not provided by the EZ1 kit). 
 
3.1.5 NUCLEIC ACIDS EXTRACTION WITH NUCLISENSE 
A second CE IVD instrument, the NucliSENS®easyMag®, has been used as reference 
method for the evaluation of our extraction kit. It is an automated system for total 
nucleic acid extraction from different sample types and volumes. 
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3.1.6 SAMPLES 
The samples involved in the study are composed by synthetic samples, clinical 
specimens and samples derived from International EQA (External Quality Assessment). 
The synthetic samples are obtained spiking the pathogen or its DNA/RNA into synthetic 
matrices or transport buffers, such as AcroMetrixTM EDTA Plasma Dilution Matrix 
(Thermo Fisher Scientific) or PBS 1X (Sigma Aldrich). The pathogens used for the spiked 
samples are: 
1) The 1st WHO International Standard for Human Cytomegalovirus (CMV) (WHO 
International Laboratory for Biological Standards, UK). The preparation contains 
the HCMV Merlin strain in a universal buffer comprising Tris-HCland human 
serum albumin and found negative for HBsAg, anti-HIV and HCV RNA; 
2) The 1st WHO International Standard for Epstein-Barr Virus (EBV) (WHO 
International Laboratory for Biological Standards, UK). The preparation contains 
the EBV B95-8 strain in a universal buffer comprising Tris-HCl, human serum 
albumin and trehaloseand found negative for HBsAg, anti-HIV and HCV RNA; 
3) Plasmids (pls) pEX-A2 (Eurofin Genomics) containing a sequence of CMV. 
For mimics negative samples the matrices have been used without adding any 
pathogens. 
A total of 381 clinical specimens has been included in this study. A detailed list is 
reported in table 13. 
 
   
Table. 13.  List of clinical samples extracted in the study. CMV: Human CitomegaloVirus; EBV: Epstein-Barr 
Virus; HHV6: Human Herpesvirus 6; HHV8: Human Herpesvirus 8; ENTERO; Enterovirus; AVD: Adenovirus; 
HSV1-2: Herpesvirus 1-2; STI: Sexual Transmitted Infections; HPV: Human Papillomavirus. BAL; 
BronchoAlveolar Lavage; CSF: Cerebral Spinal Fluid. 
51 
 
In order to evaluate the proficiency of our automated kit, some quality panels have 
been used. The QCMD (Quality Control for Molecular Diagnotics) analyzed in the study 
are reported in table 14. 
 
Table. 14.  List of QCMD extracted in the study. CMV: Human CitomegaloVirus; EBV: Epstein-Barr Virus; 
JCV: John Cunningham Virus; BKV: Poliomavirus BK; ENTERO; Enterovirus; AVD: Adenovirus; VZV: Varicella 
Zooster Virus; HSV: Herpesvirus1-2; Parvo B19: Parvovirus B19. 
 
3.1.7 REAL TIME PCR KIT FOR PATHOGEN QUANTITATIVE DETECTION 
The real time PCR analysis has been chosen to evaluate the extraction efficiency. We 
selected this method because is fast and simply, and the analysis allows to verify 
different important parameters:  
1) The quality of the extract, which can be verified by the amplification plot: the 
presence of contaminants in fact inhibits the amplification curve;   
2) The extraction efficiency of the Internal controls, which is verified by their Ct 
values; 
3) The extraction efficiency of the pathogen, which is verified by its quantification 
in LOG10 copies/ml, where copies/ml is:  (copies/rx) x Ve x (1000/Vs). Copies/rx 
stands for copies per reaction; Ve for the Elution Volume; Vs for the starting 
volume of the processed sample; 
4) The extraction repeatability: The extraction efficiency in a same session is 
analyzed by the Coefficient of Variation (CV), that is evaluated according to the 
following calculation:  
 
Ct SD: Standard deviation of the mean Ct of the extracts of the session; Mean Ct: The mean of the Ct of the 
extracts processed in the same session. 
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For the real time PCR analysis molecular diagnostic kits provided by AB ANALITICA for 
the detection of infectious diseases have been used. In details they are reported in 
table 15: 
 
Table. 15.  List of molecular diagnostic kit used in the study for the detection of various pathogens. 
In addition to the pathogen, this kits allow to detect the internal controls used for the 
extractions. 
The experiment of the study have been conducted on the real time PCR BioRad DX 
instrument (BioRad). 
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3.2 RESULTS  
 
3.2.1 OPTIMIZATION OF EXTRACTION PROTOCOL 
In the first part of my Ph.D project, I developed a prototype for a new automated 
extraction kit to be used with the workstation GENEQUALITY X120. Several solutions 
have been tested to obtain an efficient packaging of the kit. Finally, the extraction 
reagents have been included into two sealed cartridges and a series of tubes as shown 
in figure 16. 
 
.  
Fig. 16. GENEQUALITY X120 Pathogen kit. 
 
The device has been called GENEQUALITY X120 Pathogen kit and it allows to extract up 
to 96 samples. 
Several conditions have been evaluated for the design of the automated process. To 
sum up, once loaded in the workstation the samples to be, the automated extraction kit 
and the necessary plastics (such as tips), the system can start without any other actions 
by the operator. The extraction process occurs in a work plate where the samples, the 
internal controls and the extraction reagents are dispensed. For each extraction step, 
the work plate is moved through different position of the workstation, from the 
thermo-shakers to the magnet. Finally the eluates are recovered in a storage plate 
without the magnetic beads. To simplify the application of this platform, an easy-to-use 
interface for the user have been developed, which serves to set the extraction 
conditions, among which: N° of sample to be extracted, Volume of sample to process 
(Vs), Elution Volume (Ve). 
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Finally, several parameters have been tested to obtain an efficient automated 
extraction method.  
 
3.2.1.1 EVALUATION OF EXTRACTS QUALITY  
Different experiment tests have been done to evaluate the quality of the extracts 
obtained with our automated extraction kit. The results show that the real time PCR 
plots present good amplification curves of the extracted internal controls (IC DNA and IC 
RNA), indicating the absence of possible extraction contaminants (protein, ethanol…) in 
the eluates. 
 
3.2.1.2 EVALUATION OF OPTIMAL STARTING VOLUMES 
For this evaluation we decided to verify the efficiency of the our automated extraction 
method starting from 200 µl and 400 µl of sample. For this experiment, eight aliquots of 
human plasma have been extracted with the GENEQUALITY X120 Pathogen kit in the 
same session. In parallel an operator with the same reagents has performed the 
extraction manually. Two aliquots have been also extracted with a reference CE IVD 
instrument. The extractions have been performed processing 200 µl and 400 µl of 
sample and eluting in 90 µl. The results are shown in table 16.  
 
 
 
Table 16. Mean Ct and CV values for the controls IC DNA and IC RNA extracted in manual, in automation 
and with the BioRobot EZ1 starting from 200 µl and 400 µl (Vs). The CV has not been calculated for the 
two extracts of the BioRobot EZ1. 
 
The Mean Ct values relative to the GENEQUALITY X120 Pathogen kit results (Automated 
extractions) are comparable to those relative to the manual kit (Manual extractions) 
and to the reference method (BioRobot EZ1). These data indicates that the extraction 
efficiency for both DNA (IC DNA) and RNA (IC RNA) of our method is equivalent to the 
references, starting from both 200 µl and 400 µl of sample. Moreover, the CV values 
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show that the automated process has a good repeatability, comparable to the manual 
extraction.  
 
3.2.1.3 EVALUATION OF OPTIMAL ELUTION VOLUMES 
For this evaluation we decided to consider three different elution volumes: 90 µl, 120 
µl, 180 µl. For this experiment, eight aliquots of human plasma spiked with WHO CMV 
(final concentration of 2500 UI/ml) have been extracted with the GENEQUALITY X120 
Pathogen kit in three consecutive sessions, varying the elution volume. The experiment 
has been performed starting from both 200 µl and 400 µl of sample.  Two aliquots have 
been also extracted with a reference CE IVD instrument. The results are shown in table 
17. 
 
 
 
Table 17. Mean Ct and CV values for the target WHO CMV, the controls IC DNA and RNA extracted with 
different elution volumes (90 µl, 120 µl, 180 µl Ve) and with the reference method BioRobot EZ1, starting 
from 200 µl and 400 µl of sample (Vs). The quantification of the target WHO CMV is also reported as a 
mean value among the extracts values (Mean LOG copies/ml). The CV has not been calculated for the two 
extracts of the BioRobot EZ1. 
 
As the table shows, the quantification of the target is comparable for all elution 
volumes, both starting from 200 µl and 400 µl of sample. Moreover, the DNA and RNA 
extraction efficiency of our automated kit is confirmed by the CV values of the target 
and the internal controls and by their Ct comparability with the BioRobot EZ1. 
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3.2.1.4 EVALUATION OF OPTIMAL CARRIER CONCENTRATION 
The previous experiments have been conducted with a carrier concentration of 18 µg 
per sample. With the following experiment we have tried to decrease the concentration 
of carrier in order to verify that the extraction efficiency is maintained even with lower 
carrier concentrations.  For this experiment, eight aliquots of human plasma spiked with 
WHO EBV (final concentration of 2500 UI/ml) have been extracted with the 
GENEQUALITY X120 Pathogen kit in three consecutive sessions, varying the carrier 
concentration: 18 µg per sample, 9 µg per sample and 3 µg per sample. Two aliquots 
have been also extracted with a reference CE IVD instrument. The extractions have 
been performed processing 400 µl of sample and eluting in 90 µl. The results are 
reported in table 18. 
 
 
Table 18. Mean Ct and CV values for the target WHO EBV and the control IC RNA extracted with different 
concentration of carrier (18 µg per sample, 9 µg per sample and 3 µg per sample) and with the reference 
method BioRobot EZ1. The quantification of the target WHO EBV is also reported as a mean value among 
the extracts values (Mean LOG copies/ml). The CV has not been calculated for the two extracts of the 
BioRobot EZ1. 
 
The values obtained reveal that the quantification of the target is comparable among 
the extraction with the different carrier concentrations, indicating that decreasing the 
carrier quantity the DNA extraction efficiency is not lost. Similar results are obtained for 
the RNA extraction, considering the Mean Ct of the IC-RNA. Moreover, the DNA and 
RNA extraction efficiency of our automated kit is confirmed by the CV values of the 
target and the internal controls and by their Ct comparability with the BioRobot EZ1. In 
conclusion, the carrier concentration of the GENEQUALITY X120 Pathogen kit has been 
switched from 18 µg to 3 µg per sample. 
 
 
 
 
57 
 
3.2.1.5 EVALUATION OF THE ABSENCE OF CROSS-CONTAMINATION 
The absence of cross-contaminations during a specific process is a mandatory 
requirement because if cross-contamination occurs, it is the first cause of false positive 
results. The following experiment has been done to verify the absence of cross-
contaminations in our automated process. For this evaluation, twenty-four aliquots of 
CMV pls (final concentration of 104 copies/µl in PBS 1X and twenty-four aliquots of only 
PBS 1X have been extracted in the same session with the GENEQUALITY X120 Pathogen 
kit. In order to increase the possibility of cross-contaminations among the wells of the 
work plate, the samples to be extracted have been arranged in the platform in such a 
way to be checkerboard dispensed (Fig. 17). The extraction have been  performed 
processing 400 µl of sample and eluting in 90 µl. 
 
 
Fig. 17.  Checkerboard dispensation of the sample in the work plates. 
 
In the first experiment, more than 50% of the negative extracts were positive for the 
viral target (false positive), indicating that the cross-contamination phenomenon 
occurred. Considering the steps of the protocol, the binding may have been most 
crucial for cross-contamination: in this step the liquid volume in the work plate wells is 
greater than in the other and then a liquid transfer among the wells may occur during 
the shaking. Therefore, different shaking speed of the binding have been tested to set 
the better one to avoid the cross-contaminations (Table 19). 
 
 
 
 
Table 19. Number of false positive obtained on 24 negative samples, changing the shaking speed of the 
binding step (1200-900-750 rpm).  
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As the data reveal, the 750 rpm option is the best to avoid cross-contaminations. To 
confirm this result, other extractions with this condition has been performed (Table 20). 
 
 
Table 20. Number of false positive obtained on 24 negative samples, with the 750 rpm shaking speed in 
three different extractions. 
 
In order to verify that the extraction efficiency has not been lost by decreasing the 
shaking speed of the binding step, the positive samples (PBS 1X + CMV pls) extracted 
with GENEQUALITY X120 Pathogen kit in the three experiments with the 750 rpm, have 
been compared with the two aliquots of the same positive sample extracted with a 
reference CE IVD device in the same conditions. The results are shown in the table 21.  
 
 
 
 
Table 21. Mean Ct and CV values for the target and the control  IC DNA.  The quantification of the target 
CMV pls is also reported as a mean value among the extracts values (Mean LOG copies/ml). The values 
are grouped by the three experiments performed with the shaking speed 750 rpm for the binding step 
(Experimet 1-2.3). For each experiment the values relative to the extraction with the reference method 
BioRobot EZ1 are reported, expect for the CV. 
 
As the data of the table reveals, the values obtained in the three experiments with our 
automation process are comparable to those relative to respective BioRobot EZ1. 
Moreover, the extraction efficiency is confirmed by the CV values of the target and 
internal control (IC DNA). 
In conclusion, the shaking speed setted for our automated extraction protocol has been 
switched from 1200 to 750 rpm. 
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3.2.2 VALIDATION OF GENEQUALITY X120 PATHOGEN KIT PROTOTYPE 
 
After achieving the prototype standardization of the automated extraction kit, a phase 
of the project dedicated to the evaluation of its diagnostic performance has been 
started and the following parameters has been investigated. 
 
3.2.2.1 REPEATIBILITY AND REPRODUCIBILITY EVALUATION 
The repeatability and the reproducibility have been investigated by Intra- and Inter-
Assay experiments. 
The intra-assay experiment verifies the repeatability of the process within the same 
extraction session. For this evaluation, forty-eight aliquots of human plasma spiked with 
WHO EBV (final concentration of 2500 UI/ml) have been extracted in the same session. 
The experiment have been performed processing both 200 µl and 400 µl of sample and 
eluting in 90 µl. The results are reported in table 22. 
 
 
 
Table 22. Mean Ct and CV values for the target and the controls IC DNA and IC RNA extracted with the 
developed automated process, starting from 200 µl and 400 µl of sample (Vs). The quantification of the 
target WHO EBV is also reported as a mean value among the extracts values (Mean LOG copies/ml). 
 
The intra-assay repeatability is indicated by the CV values for the different targets. As 
shown, the intra-assay repeatability of the developed automated process is always <2% 
for the different DNA and RNA target (WHO EBV, IC DNA and IC RNA), starting from 
both 200 µl and 400 µl of sample. 
 
The inter-assay experiment verifies the reproducibility of the process among different 
extraction sessions. For this evaluation, sixteen aliquots of human plasma spiked with 
WHO EBV (final concentration of 2500 UI/ml) have been extracted in three consecutive 
sessions, changing the batches of reagents in order to increase the variability. The 
experiment have been performed processing both 200 µl and 400 µl of sample and 
eluting in 90 µl. The results are shown in table 23. 
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Table 23. Mean Ct and CV values for the target and the controls IC and IC-RNA relative to the three 
different extraction (Extraction 1-2-3) with the developed automated method, starting from 200 µl and 
400 µl of the sample (Vs). The quantification of the target WHO EBV is also reported as a mean value 
among the extracts values (Mean LOG copies/ml). 
 
The Inter-Assay reproducibility has been evaluated calculating the CV among the Mean 
Ct of the three extractions (Table 24). 
                                     
 
 
Table 24. The table shows the obtained inter-assay reproducibility for the 3 extractions performed 
starting from 200 ul and 400 ul OF SAMPLE (Vs). 
 
The data reveal that the Inter-Assay Reproducibility is always <1,5% for both DNA and 
RNA extractions (WHO EBV, IC DNA, IC RNA) and starting from the different volume 
samples. 
 
3.2.2.2 ANALYTICAL SENSITIVITY EVALUATION 
The experiment evaluating the analytical sensitivity or detection limit investigates the 
minimum viral load that developed automated process is able to extract with 95% of 
confidence. For the evaluation, two samples with serial dilutions respectively of WHO 
CMV and WHO EBV have been prepared in human plasma to obtain these 
concentrations: 
1) 250 UI/ml; 
2) 200 UI/ml; 
3) 125 UI/ml; 
4) 62,5 UI/ml; 
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5) 50 UI/ml. 
Eight aliquots for each concentration have been extracted in the same session. The 
extractions have been performed processing 400 ul of sample and eluting in 90 ul. The 
extracts have been tested in triplicate by real time PCR. The results have been analyzed 
by Probit with a confidence of 95% (Fig. 18). 
 
 
Fig. 18. Analysis Probit for the WHO EBV (a) and WHO CMV (b) targets in plasma samples. 
 
The results indicate that the GENEQUALITY X120 Pathogen kit has a probability of 95% 
to detect a viral load of 99,2318 UI/ml for the WHO EBV and of 106,8862 UI/ml for the 
WHO CMV. 
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3.2.2.3 LINEAR RANGE EVALUATION 
The linear range is  the  range  within  the  working  range  where  the  results  are  
proportional  to  the  concentration of the analyte or measurand present in the sample. 
For the evaluation, two samples with serial dilutions respectively of WHO CMV and 
WHO EBV have been prepared in human plasma to obtain these concentrations: 
1) 5 x 105 UI/ml; 
2) 5 x 104 UI/ml; 
3) 5 x 103 UI/ml; 
4) 5 x 102 UI/ml; 
5) 2,5 x 102 UI/ml; 
6) 1,25 x 102 UI/ml. 
Six aliquots for each concentration have been extracted in the same session, processing 
400 µl of sample and eluting in 90 µl. The results are shown in figures 19 and 20: 
 
 
Fig. 19. Graphic representation of the linearity range experiment obtained for the WHO EBV target. 
 
Fig. 20. Graphic representation of the linearity range experiment obtained for the WHO CMV target. 
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The data show that the GENEQUALITY X120 pathogen kit allows to extract in a linear 
way in a range of 125-5 x 105 UI/ml for the WHO EBV and of 250-5 x 105UI/ml for the 
WHO CMV target. 
 
3.2.2.4 EXTRACTION EFFICIENCY EVALUATION 
At least 300 clinical samples have been extracted with the GENEQUALITY X120 
Pathogen kit to test its extraction efficiency. The clinical samples analyzed were positive 
for different targets with different viral load. Different types of clinical specimens have 
been included (table 13).  
 
   
 
Table. 13.  List of clinical samples included in the study. CMV: Human CitomegaloVirus; EBV: Epstein-Barr 
Virus; HHV6: Human Herpesvirus 6; HHV8: Human Herpesvirus 8; ENTERO; Enterovirus; AVD: Adenovirus; 
HSV1-2: Herpesvirus 1-2; STI: Sexual Transmitted Infections; HPV: Human Papillomavirus. BAL; 
BronchoAlveolar Lavage; CSF: Cerebral Spinal Fluid. 
 
The same samples have been extracted with reference CE IVD devices (BioRobot EZ1, 
NucliSENS EasyMag). The results indicate that in >90% of cases the GENEQUALITY X120 
Pathogen kit shows comparable performances to the NucliSENS EasyMag device. In the 
remaining 10%, the positive results obtained with the NucliSENS has been lost with the 
GENEQUALITY X120 Pathogen kit but resulted negative also with the BioRobot EZ1, 
indicating that probably these clinical samples have been degraded due to repeated 
thawing cycles. 
In order to increase the number of specimens investigated, also QCMD samples have 
been extracted with the developed automated process (Table 14). 
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Table. 14.  List of QCMD extracted in the study. CMV: Human CitomegaloVirus; EBV: Epstein-Barr Virus; 
JCV: John Cunningham Virus; BKV: Poliomavirus BK; ENTERO; Enterovirus; AVD: Adenovirus; VZV: Varicella 
Zooster Virus; HSV: Herpesvirus1-2; Parvo B19: Parvovirus B19. 
 
The same samples have been extracted with a reference CE IVD devices (BioRobot EZ1). 
The study reveals that the extraction performance of the GENEQUALITY X120 Pathogen 
kit are comparable to those of the reference method. Moreover, the quantification of 
the targets are inner the range declared by the QCMD, indicating a good extraction  
efficiency of our process. 
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4. PART II: EVALUATION OF HCV GENOTYPING WITH 
AMPLIQUALITY HCV TYPE PLUS DEVICE 
 
The second part of my PhD project, I focused on the performance evaluation of the 
AMLIQUALITY HCV TYPE PLUS kit, intended for the genotyping of HCV.  
 
4.1 MATERIALS AND METHODS  
 
4.1.1 AMPLIQUALITY HCV TYPE PLUS KIT 
The AMPLIQUALITY HCV TYPE PLUS device is a kit based on the Reverse Line Blot 
technique (RLB) for the determination of the genotypes 1-7 of HCV. The AMPLIQUALITY 
HCV TYPE PLUS kit provides the necessary equipment for the assay starting from the 
HCV RNA extracted. The HCV RNA undergoes a multiplex RT-PCR (Retrotranscription 
and PCR in a single step) for the 5'UTR and CORE regions with biotinylated primers. The 
reaction mix includes also a dUTP/Cod UNG system that is active at room temperature 
and removes any contamination of previous reactions. The PCR products are then 
hybridized to oligonucleotide probes that are spotted on a laminated nitrocellulose 
membrane and recognize specific sequences of the 5’UTR and CORE regions. The 
hybridization process is followed by a series of washes to eliminate the non-specific 
binding. Finally, a colorimetric reaction (streptavidine-alkaline phosphatase conjugated 
plus substrate) underlies with brownish bands the positions in which the hybridization 
occurred. At the end of the assay the strips show different band patterns that allow the 
identification of the genotype and in most cases the subtypes of the virus. The kit 
provides also an Internal Control RNA (IC-RNA) for the efficiency monitoring of the 
extraction process and the RT-PCR. This control consists in the MS2 phage of E. Coli, 
which is stable and absence from the clinical samples. Moreover, a DNA positive control 
representative of a genotype 1a sequence is supplied for the monitoring efficiency of 
the genotyping process.  
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The Figure 21 shows an example of strip of the kit AMPLIQUALITY HCV TYPE PLUS. It 
includes: 
A. Two red marker lines facilitate the correct position of the strips on the reading 
card or interpretation sheet; 
B. STAINING CTRL: It is the staining control band that allows 
the user to assess the staining reaction (substrate 
conversion); 
C. INTERNAL CTRL: It recognizes the internal control (IC-RNA), 
thus permitting the assessment of the quality of HCV RNA 
extract, which provides indications concerning successful 
completion of the extraction and RT-PCR to avoid false 
negative results; 
D. HCV UNI 5’UTR: it shows the presence of a PCR product 
from the 5’UTR; 
E. HCV UNI CORE: It shows the presence of a PCR product from 
the CORE region, thid band has to be considered in case that 
the genotype-specific bands for the 5’UTR indicate that the 
sample is positive for genotype HCV 1; 
F. Sixteen bands (position 1 to 16) containing oligonucleotide 
probes that recognize sequences of the 5’UTR in a 
genotype-dependent manner; 
G. Three bands (position 17 to 19) containing oligonucleotide 
probes that recognize sequences of the CORE in a genotype-
dependent manner. 
At the end of the assay, the interpretation of the band patterns is based on specific 
interpretative tables that are shown in the Appendix 4. The interpretation tables 
comprises two sections: Part A, dedicated to the identification of genotype 6 and 
subtypes 1a and 1 b using the information from both the 5’UTR and  the CORE regions, 
and Part B, dedicated to the identification of genotypes 2, 3, 4, 5 and 7 according to the 
information from the 5’UTR. If the strip shows any of the 5’UTR band patterns that 
correspond to the patterns described in table A (HCV genotyping 1 or 6), the user 
proceeds to the analysis of the CORE region band patterns and will base the genotyping 
solely on this analysis. If there are no bands for the CORE region or the results for the 
CORE region are inconclusive, genotype 1 and 6 cannot be reliably distinguished and 
identification of HCV genotype 1 has to be based on the information provided by the 
5’UTR. 
To simply the use of these tables, an interpretative software has been developed and 
called HCV TYPE PLUS Strip Reader (Fig. 22).   
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Using a straightforward point and click interface, the user inputs the results from the 
strip into the interpretation software. The software evaluates the data and produces a 
report. 
 
                  
                                        
Fig. 22. Mask shown by HSCV TYPE PLUS Strip reader. 
 
In the first window on the right, the following data are shown: 
1) If the strip is OK: presence of staining control and IC-RNA signal; 
2) Genotyping results; 
3) Subtyping result (if appropriate). 
In the second window other details of the evaluation are shown: 
1) The region information used for the interpretation: 5’UTR, CORE or both; 
2) The alphanumeric code corresponding to the matching pattern in the 
interpretation tables. 
 
4.1.2 AUTOBLOT 
The validation studies of AMPLIQUALITY HCV TYPE PLUS have been conducted with the 
Autoblot 3000H instrument (MedTec). The AutoBlot 3000H fully automates the Line 
blot assays. Following the manual addition of test samples, the AutoBlot incubates, 
washes, and performs subsequent reagent additions as defined by the operator during 
the programming phase. It permits easy setup with walk-away performance, sounding 
an alarm when the test is complete. The 3000H model has a heated platform, magnetic 
stirrer, and heated bottle plate for hybridizations and stringent washes that require 
heat. The unit is fully programmable from the front panel and stores up to ten protocols 
within the unit, allowing for full customization of blot assays for dispense, incubation, 
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and aspiration. The AutoBlot dispenses and aspirates up to twenty strips in 90 seconds. 
The experiments of this study have been conducted according to the following protocol 
(Table 24). 
 
 
Table 24. Scheme of the protocol for the visualization on strip 
 
4.1.3 GENEQUALITY X120 PATHOGEN KIT 
The samples analyzed for the evaluation study of the AMPLIQUALITY HCV TYPE PLUS kit 
have been extracted with the GENEQUALITY X120 Pathogen kit, developed in the first 
part of this project. In particular, the extraction have been performed processing 400 µl 
of sample and eluting in 90 µl. 
 
4.1.4 SEQUENCING NS5B REGION 
The NS5b sequencing is still the gold standard method for HCV genotyping. In order to 
confirm the results of RLB genotyping, the NS5b sequencing have been performed. The 
RT-PCR was made with specific primers for NS5b region, previously reported by 
Sandres-Sauné et al [105]; the same enzyme mix utilized for our HCV genotyping test 
has been used, but with a different thermal profile, that fitted to melting temperature 
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of these primers. The table 25 summarizes the thermal profile used for the NS5b 
amplification. 
 
 
Table 25. Thermal profile of NS5b sequencing. 
 
The amplified products have been purified by using ExoSap-IT® (Affymetrix), according 
to the manufacturer’s protocol. Reaction of sequencing was performed by BMR 
Genomics, with the BigDyes terminator cycle sequencing kit v3.1 (Applied Biosystems). 
The sequencing reactions were run on ABI 3730XL (Applied Biosystems) and ABI 3100 
(Applied Biosystems) and were analyzed with FinchTV software v1.4 (Geospiza). The 
resulted sequences are then analyzed using the program BLAST (Basic Local Alignment 
Search Tool) available at NCBI (National Center for Biotechnology Information) to obtain 
the corresponding genotype. 
 
4.1.5 ANALYSIS OF HCV RNA EXTRACTS WITH THE ARTUS HCV RG RT-PCR Kit 
The clinical samples used in the evaluation study have been previously tested with the 
Artus HCV RG RT-PCR Kit (Qiagen) to confirm the absence or presence of HCV RNA. This 
analysis have also provided the viral load of HCV in the positive samples.   
 
4.1.6 SAMPLES 
The samples included in the study are synthetic samples, clinical specimens and samples 
derived from International EQA (External Quality Assessment). 
The synthetic samples are obtained spiking the virus or the synthetic nucleic acid into 
the matrix, such as AcroMetrixTM EDTA Plasma Dilution Matrix (Thermo Fisher 
Scientific). In particular are used: 
1) The 4th WHO International Standard for Hepatitis C Virus (HCV) (WHO 
International Laboratory for Biological Standards, UK). The standard consists of 
genotype 1a HCV antibody negative, HCV RNA-positive plasma, diluted in pooled 
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human plasma and found negative for HIV-1 RNA, HBV DNA, HAV RNA and 
parvovirus B19 DNA; 
2) Plasmids (pls) pEX-A2 (Eurofin Genomics) containing the 5'UTR and the CORE 
regions of the subtypes HCV 6c, 6d, 6e, 6l and 6n and the genotype 7a. 
 
The clinical specimens analyzed in the study are reported in table 26: 
 
Table 26. List of sample used in the evaluation study. 
 
In order to evaluate the proficiency of our genotyping kit, also some quality panels have 
been used, such as the HCV Acrometrix control (Thermo Fisher Scientific) 
 
4.1.7 INTERFERING SUBSTANCES 
In order to test the possible interfering substances, we used the Acrometrix Inhibition 
Panel (Thermo Scientific) and in addition the hemoglobin (Table 27). 
 
 
 
Table 27. List of substances and their concentration that have been evaluated as possible interfering 
substances.  
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4.2 RESULTS  
 
The experiments for the evaluation study of the AMPLIQUALITY HCV TYPE PLUS kit have 
been carried out according to the UNI EN 13612 and as defined by the CTS (Common 
Technical Specification) for in vitro diagnostic medical devices (Common Decision of the 
30 November 2009). In particular, the following parameters have been investigated. 
 
4.2.1 REPEATIBILITY AND REPRODUCIBILITY EVALUATION 
The repeatability and the reproducibility of the AMPLIQUALITY HCV TYPE PLUS device 
have been investigated by Intra- and Inter-Assays. 
The intra-assay experiment investigates the repeatability of the result using the same 
reagents and instruments. For this evaluation, three positive HCV RNA extracts with 
different viral load and below 100.000 UI/ml have been tested ten times by the same 
operator on the same day and using the same batch of reagents. The results are shown 
in table 28.  
 
 
Table 28. Viral load of the three sample tested, their expected genotype and the obtained results. 
 
The data of the table reveal that for 29 of 30 cases the AMPLIQUALITY HCV TYPE PLUS 
kit has detected the expected genotype (valid result). The only non valid result has 
reveal a genotype 1 without subtyping the 1b. These data indicate that the intra-assay 
repeatability for the kit in validation is >96%. 
 
The inter-assay experiment verifies the reproducibility of the result among different 
sessions, varying factors that could contribute to the inaccuracy of the method. For this 
evaluation, three positive HCV RNA extracts with different viral load have been tested 
four times by different operators and varying the thermal cycler. The results are 
reported in table 29.  
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Table 29. The table shows the viral load of the three sample tested, their expected genotype, the 
operator (1-2) and the thermo cyclers used, and the obtained valid results with the kit in validation. 
 
The data reveal that for the Operator 1 and the thermo cycler ABI 2720 (Applied 
Biosystem) the AMPLIQUALITY HCV TYPE PLUS kit has detected the expected genotype 
(valid result) in all the tests carried out, whereas for the Operator 2 and the thermo 
cycler My Cycler (BioRad) in 11 of 12 cases. The non valid result has reveal a genotype 1 
without subtyping the 1b.  
 
4.2.2 ANALYTICAL SPECIFICITY EVALUATION 
The experiment evaluating the analytical specificity verifies the ability of the 
AMPLIQUALITY HCV TYPE PLUS kit to detect the target without any cross-reactivity. This 
cross-reactivity has been considered and analyzed in silico during the design and 
selection of primer and probes of the kit. The cross-reactivity has been verified also in 
vitro, testing samples negative for HCV RNA and positive for other pathogens (Table 30). 
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Table 30. List of the pathogens tested for the in vitro cross-reactivity experiment. The viral load results 
obtained with the AMPLIQUALITY HCV TYPE PLUS kit are also reported. 
 
As data show, all the samples tested with AMPLIQUALITY HCV TYPE PLUS has resulted 
negative, confirming the absence of cross-reactivity. 
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4.2.3 ANALYTICAL SENSITIVITY EVALUATION 
The experiment evaluating the analytical sensitivity investigates the lower viral load of 
HCV detectable with 85% of confidence (detection limit). For this evaluation, serial 
dilutions of the WHO HCV have been prepared in human plasma to obtain these 
concentrations: 
1) 26.000 UI/ml; 
2) 13.000 UI/ml; 
3) 6.500 UI/ml; 
4) 3.250 UI/ml; 
5) 1.625 UI/ml; 
6) 812.5 UI/ml 
Five aliquots for each concentration have been extracted. The obtained eluates have 
been collected in a tube to form a single RNA extract solution for each dilution. Then, 
the HCV RNA extracts have been tested in three separate PCR sessions and in six 
replicates per session. The results have evaluated by Probit with a confidence interval of 
95% (Fig. 23). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 23. Result of the probit analysis for 
determination of the detection limit of the kit AMPLIQUALITY HCV TYPE PLUS 
 
The calculated detection limit of the AMPLIQAULITY HCV TYPE PLUS is  1.9044 UI/ml. 
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4.2.4 DIAGNOSTIC SPECIFICITY EVALUATION 
The experiment for the evaluation of the diagnostic specificity of AMPLIQUALITY HCV 
TYPE PLUS kit investigates the ability of the kit to detect the absence of genotype in 
known HCV RNA negative clinical samples. For this evaluation, 155 samples have been 
extracted and analyzed with our genotyping kit. The results show that the presence of 
the control bands and the absence of the genotyping bands are confirmed in all the 155 
strips tested. Therefore, the diagnostic specificity of the AMPLIQUALITY HCV TYPE PLUS 
device resulted 100% (Fig. 24). 
 
 
Fig. 24. Formula for the determination of the diagnostic specificity. TN (True Negative): N° of samples 
analyzed with our genotyping kit and resulted correctly negative; FP (False Positive): N° of samples 
analyzed with our genotyping kit but resulted positive. 
 
4.2.5 DIAGNOSTIC SENSITIVITY EVALUATION 
The experiment for the evaluation of the diagnostic sensitivity of AMPLIQUALITY HCV 
TYPE PLUS kit investigates the ability of the kit to detect the expected genotype. For this 
study, 264 clinical samples with different viral load have been analyzed (Fig. 25). 
 
 
Fig. 25. List of clinical samples analyzed in the study, grouped by genotype and viral load. 
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The genotyping resulted are reported in table 31. 
 
 
Table 31. Summary of the genotyping results obtained using the kit AMPLIQUALITY HCV TYPE PLUS. 
 
To verify the genotyping efficiency of our kit, the same extracts have been also 
sequenced for the NS5b region. This comparison has been possible only for 246 
extracts, because for 18 extracts we obtained a failure of sequencing.  The comparison 
results are shown in table 32. 
 
 
Table 32. Summary of the genotyping results obtained using the kit AMPLIQUALITY HCV TYPE PLUS and 
the sequencing of the NS5b (reference method). 
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As shown by the data, the genotypes resulted are comparable to those obtained by the 
sequencing. Regarding the subtyping of 1a and 1b, the AMPLIQUALITY HCV TYPE PLUS 
kit has detected the correct subtype in 129 cases on 131. In two cases the 
AMPLIQUALITY HCV TYPE PULS has detected a genotype 1 without subtyping them 
respectively in 1a and 1b. 
 
In order to test also rare genotypes, synthetic plasmids for the subtypes 6c, 6d, 6e, 6l 
and 6n and the genotype 7a have been analyzed. They have not been extracted but 
added at a concentration of 104copies/µl to the RT-PCR reaction. The obtained strip are 
shown in figure 26. 
 
 
Fig 26. Genotyping results obtained using the kit AMPLIQUALITY HCV TYPE PLUS for the genotype 6 and 7. 
 
The AMPLIQUALITY HCV TYPE PLUS is able to correctly detect the genotype 7a, and the 
subtypes of the 6, except for the subtype 6d that is detected as genotype 1. 
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4.2.6 INTERFERING SUBSTANCES EVALUATION 
The experiment for the evaluation of possible interfering substances verifies the ability 
of the AMPLIQUALITY HCV TYPE PLUS kit to detect the correct genotype in presence of 
substances that may alter the result. For this evaluation, endogenous and exogenous 
substances have been tested (table 27).  
 
 
 
Table 27. List of substances and their concentration that have been evaluated as possible interfering 
substances.  
 
For each interfering substance, two plasma samples have been prepared with a 
concentration of 2x105 UI/ml of the HCV Acrometrix control plus the addition of the 
interfering substance at the final concentration shown in table 27. Two positive plasma 
samples without any substances have been tested as control. The prepared samples 
have been extracted and ten replicates of each extract have been tested for the 
genotype with our kit. The number of replicates have been chosen according to the 
Maximum Likelihood method, considering a significance level of 0,05. For the 
interpretation of results, a binomial distribution has been used: 
 
Two or less non valid genotypes (different from the expected) have been accepted as a 
kit variability and in this case the H0 was accepted. On the contrary, for more than two 
non valid genotypes the H0 was rejected in favor of the H1.  
As the table 34 reports, only the heparin resulted to interfere with the assay of the kit in 
validation. In fact, the heparin is known to be a potent inhibitor of the PCR polymerase. 
 
-H1: the interfering substance alters the resulted genotype; 
-H0: the interfering substance do not alter the resulted genotype.  
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Table 34. Summary of the results of the interfering substances experiment. 
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5. DISCUSSION 
 
Although the incidence of HCV infection declined in the 1990s with the introduction of 
improvements in infection control and safer injection practices, a large number of 
persons worldwide results still HCV positive. Nowadays, the research aims to formulate 
a pangenotypic regimen based on the new DAAs combination therapies, but 
nevertheless the HCV genotype information is still required to choose the best anti-viral 
treatment for the patient. Because of the high demand for this type of analysis and the 
request of standardized procedures by the specialized laboratories, we decided to 
develop a high-throughput system for the HCV genotyping. The goal of our project is 
developing a process starting from the clinical sample up to the genotype result, which 
includes the HCV RNA extraction, the RT PCR and the genotyping (Fig 14). 
 
 
Fig. 14.  Scheme of the modular workcells for the genotyping analysis of HCV. 
 
In the first part of my PhD project, I dealt with the development of a kit for the 
extraction of pathogen nucleic acids. To make the process as possible high-throughput, 
we decided to design this kit for its use with the platform GENEQUALITY X120 (AB 
ABANLITICA). The choice of the extraction reagents and the automated format has been 
a crucial point for the prototype development. At the end we obtained a prototype of 
GENEQUALITY X120 Pathogen kit. This kit consists in two sealed cartridges and five 
tubes that include reagents ready to use for the automated extraction of pathogen DNA 
and RNA, based on the magnetic beads technology. To make reliable the extraction 
process, we provided the kit with two types of Internal Control (IC), which assure the 
monitoring of the DNA and RNA extractions (IC DNA and IC RNA respectively), indicating 
the potential presence of inhibitors or other factors that may cause false-negative 
results. Moreover, a carrier has been added to favor the pathogen nucleic acids 
purification.   
The prototype showed good performances, confirmed by the quality of the DNA and 
RNA extracts verified by real time PCR. In addition, it revealed to be versatile, displaying 
extraction efficiency with different combination of sample and elution volumes. In 
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particular, in these work to be competitive and to satisfy the customers’ requests,  we 
have tested 200µl and 400µl as sample volumes to process and 90µl, 120µl, and 180µl 
as elution volumes. 
Another critical point in the development of the automated extraction process has 
concerned the evaluation of cross-contaminations. The first set protocol revealed 
presence of cross-contamination among the wells of the work plate because of a too 
high shaking speed during the binding step. Decreasing the shaking speed we have 
solved the problem, preserving however the extraction efficiency. 
The GENEQUALITY X120 pathogen kit validation study showed repeatability and 
reproducibility of the automated extraction process and moreover a high sensitivity of 
pathogen nucleic acids purification. In addition, the extraction efficiency have been 
evaluated analyzing more than 400 samples, regarding different matrices and DNA or 
RNA pathogen targets. The results were comparable with the reference methods. 
In addition, the GENEQUALITY X120 platform has been supplied with barcode readers in 
order to guarantee the traceability of the entire process, from the sample to the 
extract. 
Finally, since the requirements for the in vitro diagnostic medical device have been 
complied, the GENEQUALITY X120 Pathogen kit is currently CE IVD mark and 
commercialized.  
In the second part of my PhD work, I focused on the performance evaluation of the HCV 
genotyping assay. The HCV genotype is one of the factor influencing the disease 
progression and still the major predictor of the SVRs in the DAAs therapies. Thus, the 
HCV genotyping is essential to apply the most appropriate therapeutic regimen. Since 
the HCV genotypes differ at 31-34% of nucleotide positions of complete genomic 
sequencing and the subtypes about 20%, the detection of the correct HCV 
genotype/subtype requests high specific assays. The gold standard for HCV genotyping 
is the NS5B sequencing and subsequent phylogenetic analysis, but generally this type of 
assay is used by reference centers, which design homemade protocols, based on their 
specific required. Therefore, other types of assays, based on Real-Time PCR or RLB 
technologies, are commercially available. The major part of them target the viral 5’UTR, 
because it is the most conserved one. This region is able to well differentiate the virus 
at the genotype level, except for genotype 1 and 6 (subtypes c to l). Moreover, it cannot 
lead to the subtyping genotype 1, because the HCV subtype 1a segregates in two 
distinct clades, which are termed 1a clade I and 1a clade II. The 5’UTR sequence of 1a 
clade I is identical to that of subtype 1b. Recent study shows that using the sole 5’UTR 
as target for genotyping, there is a mistyping approximately of 25% and 10% of HCV 
subtype 1a and 1b strains, respectively [104]. Therefore, it is evident that the analysis of 
the sole 5’UTR is not sufficient to allow a good determination of HCV genotype/subtype 
and that evaluation of another region is necessary.  
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In this study, the AMPLIQUALITY HCV TYPE PLUS kit performances have been evaluated, 
according to the to the UNI EN 13612 and as defined by the CTS (Common Technical 
Specification) for in vitro diagnostic medical devices (Common Decision of the 30 
November 2009). This kit has previously designed in the company in order to well 
differentiate genotype 1 to 6 and subtypes 1a and 1b thanks to the presence of the 
CORE region in addition to the 5’UTR. Our assay showed a diagnostic specificity of 100% 
and a diagnostic sensitivity of 100% at genotype level and >98% at subtype level. 
A crucial point has been the recovery of samples positive for the rare genotypes, such 
as 6 and 7. To solve the problem, we decided to use synthetic constructs containing the 
5’UTR and the CORE regions of the genotype 7a and of some subtypes of the 6. 
The good subtyping results of our test are important to avoid the genotype/subtype 
misdiagnosis related to the analysis of the sole 5’UTR. In fact, this kind of mistyping 
could affect the management of the therapeutic regimen, in term of both DAAs 
combination to administered or duration of therapies, as shown by the EASL treatment 
recommendations [93]. 
In addition, the AMPLIQUALITY HCV TYPE PLUS kit is based on a RLB technique, which 
revealed to be a simple and fast method and exhibits a high sensitivity and specificity. 
The same detailed genotyping information could be achieved with Real-Time 
technologies, but is necessary performing multiple amplification reactions for each 
sample. Instead, RLB allows the acquisition of a lot of sequence information in a single 
run. RLB is also the ideal technology for identification of co-infections by different HCV 
strains. NS5b sequencing can give a definite result for genotype but evaluation of more 
HCV isolates presence in the same sample is very difficult.  
Finally, since the requirements of the CTS have been complied, the AMPLIQUALITY HCV 
TYPE PLUS is currently CE IVD mark and commercialized. 
Moreover, the use of AMPLIQUALITY HCV TYPE PLUS kit showed good performances 
starting from HCV RNA extracted with the GENEQUALITY X120 Pathogen kit. An 
important parameter which have assured the continuity of the process is the use of the 
same IC RNA by both the developed kit. 
 
In conclusion, the combination of the GENEQUALITY X120 Pathogen kit and the 
AMPLIQUALITY HCV TYPE PLUS guarantees a standardized and performing process for 
the HCV genotyping (Fig. 27). The high-throughput of this system is guarantee by the 
use of automated platform for both the extraction and the genotyping procedures 
(respectively GENEQUALITY X120 and AUTOBLOT). Moreover, the following 
experiments will aim to the use of the platform GENEQUALITY X120 for the PCR setup of 
the HCV RNA extracted, in order to avoid the introduction of possible errors done by 
the operator and to increase the high-throughput performance of the process. 
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Fig. 27.  Scheme of the modular workcells for the genotyping analysis of HCV and the developed kits used 
for this analysis. 
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Estimated prevalence of HCV infection by Global Burden of Disease regions [39]. 
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Summary of the significant trials of IFNα-free DAA regimens according to genotype 1-4 [84]. 
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Appendix 2 
 
Summary of the significant trials of IFNα-free DAA regimens according to genotype 2-3 [84]. 
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Appendix 2 
 
Summary of the significant trials of IFNα-free DAA in decompensated-cirrhotic populations [84]. 
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Appendix 3 
 
 
Treatment recommendations from EASL [93]. 
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Appendix 4 
 
Interpretative Tables for AMPLIQUALITY HCV TYPE PLUS kit, on the top the Part A of the tables is shown, at the 
bottom the Part B. 
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